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Lessons from melanoma applied to other cancers: DC-HIL is a potential biomarker and 
treatment target for breast and colon cancer
DB Harker, JE Turrentine, J Chung, PD Cruz and K Ariizumi Dermatology, The University of 
Texas Southwestern Medical Center, Dallas, TX
We previously discovered DC-HIL to be a cell-surface glycoprotein that potently inhibits T-cell 
function. We also found DC-HIL expression to be induced by melanoma on blood circulating 
myeloid-derived suppressor cells (MDSC) that promote the cancer’s progression. Using the CD14+H-
LA-DRno/low phenotype to mark MDSC in humans, we showed: (1) strong positive correlation 
between advancing melanoma stage and blood burden of DC-HIL+ MDSC; (2) quick decline of 
this blood level after surgical resection of early melanoma; and (3) restoration by anti-DC-HIL mAb 
of depressed T-cell interferon-gamma response associated with melanoma to near-normal levels. To 
determine whether this deleterious relationship between melanoma and DC-HIL+ MDSC extends to 
other cancers, we used flow cytometry to assay % DC-HIL+CD14+HLA-DRno/low cells among periph-
eral blood mononuclear cells (PBMC) from patients with metastatic breast invasive ductal carcinoma 
(n=10), colon adenocarcinoma (6), lung adenocarcinoma (9), and lung squamous cell carcinoma 
(5). Compared with 21 healthy subjects (negative control), t-test statistical analysis showed a sig-
nificant difference in the average blood DC-HIL+ MDSC burden for colon cancer (23-fold higher; 
p=0.0035) and for breast cancer (19-fold higher; p=0.0103), but not for lung adeno- and squamous 
cell carcinomas (p>0.10 and 0.08, respectively). These results indicate that blood DC-HIL+ MDSC 
may serve as a biomarker not only for melanoma, but also other cancers like breast and colon. 
Most importantly, they expand the utility of our efforts at developing mAb to neutralize the immu-
nosuppressive function of DC-HIL, thereby boosting the natural T-cell response against cancer.   
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DLX3-dependent p53 signaling network controls keratinocyte cell cycle and squamous tumor 
growth
E Palazzo,1 MD Kellett,1 C Cataisson,2 A Gormley,1 P Bible,1 V Pietroni,1 N Radoja,1 
J Hwang,1 M Blumenberg,3 SH Yuspa2 and M Morasso1 1 Laboratory of Skin Biology, National 
Institutes of Health, Bethesda, MD, 2 Laboratory of Cancer Biology and Genetics, National 
Institutes of Health, Bethesda, MD and 3 Department of Dermatology, New York University, 
New York City, NY
A balance between keratinocyte proliferation and differentiation is crucial to maintain epidermal 
homeostasis and prevent neoplastic transformation. The homeodomain transcription factor DLX3 
has been identified as a key factor involved in epidermal differentiation; however, its functions in 
keratinocytes remains to be elucidated. Through genetic, transcriptomic, and bioinformatic analysis, 
we show that DLX3 operates via suppression of cell cycle and the upregulation of differentiation 
through a p53 network. In proliferating keratinocytes, we demonstrate that DLX3 expression pro-
motes the dysregulation of pathways involved in DNA replication, cell cycle, and G1 to S blockade 
associated with p53 signature transcriptional profiles. We found that DLX3 promotes p53-dependent 
p21 transcription by physically interacting with p53 on the p21 promoter. Interestingly, DLX3 
expression is lost in human skin cancers and during progression of experimentally induced mouse 
papillomas to Squamous Cell Carcinoma. Therefore, we have reported a novel DLX3-dependent 
p53 signaling network that suggests DLX3 is a modulator of skin carcinogenesis.    
098
Periostin is a key niche component for melanoma wound metastasis
K Fukuda1, 2, E Sugihara,1 S Ohta,3 K Izuhara,4 T Funakoshi,2 M Amagai2 and H Saya1 1 
Division of Gene Regulation, Institute for Advanced Medical Research, Keio University 
School of Medicine, Tokyo, Japan, 2 Department of Dermatology, Keio University School of 
Medicine, Tokyo, Japan, 3 Department of Laboratory Medicine, Saga Medical School, Saga, 
Japan and 4 Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga 
Medical School, Saga, Japan
The phenomenon that metastatic lesion developed on injured sites has long been recognized in 
several human cancers, such as melanoma. However, factors associated with wound healing that 
attract circulating tumor cells have remained unknown. In this study, we examined the primary 
and metastatic lesions that appeared 1 month after trauma in a patient acral lentiginous melanoma. 
Microarray analysis of the primary and metastatic lesion revealed that among genes related to wound 
healing, periostin (POSTN), type I collagen, and fibronectin, genes of extracellular matrix proteins, 
were overexpressed in the metastatic lesion. The increase of these extracellular matrix proteins at 
the wound site was reproduced in a mouse model of wound healing. To examine the influence 
of wounding on metastasis, we injected B16-BL6 murine melanoma cells into footpad of nude 
mice. Whereas mice with wound developed the metastasis on the wound region, no metastasis 
was detected in mice without wound. POSTN was strongly expressed in the stroma surrounding 
melanoma cell nests in metastatic lesions of both wounded mice and the patient. Using B16-BL6 
and human melanoma cell line MeWo, we found that coating of POSTN on the plates attenuated 
the cell adhesion and promoted the migration of melanoma cells without affecting their proliferation 
in vitro. Furthermore, subcutaneously injected MC3T3-E1 cells, murine osteoblastic cell line that 
secrete large amounts of POSTN invited the metastasis of remotely-transplanted melanoma cells on 
the sites, whereas MC3T3-E1 cells with suppression of POSTN by shRNA showed a greatly reduced 
ability to promote such metastasis. Collectively these results suggest that POSTN is a key factor to 
promote melanoma cell metastasis to wound sites by providing a premetastatic niche.    
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A zebrafish model for investigating the role of SOX10 in invasive melanoma 
AL Suarez Dermatology, Weill Cornell Medical College, New York, NY
SOX10 is a key transcription factor in melanocyte lineage specification, is frequently amplified in 
melanoma, and is important for melanoma cell proliferation and survival. We hypothesize that a 
SOX10 gene signature is required for invasive melanoma phenotypes. To functionally characterize 
candidate genes identified in large-scale human genomic data sets, our lab has created a genetic 
system in a zebrafish model of melanoma. By three weeks of age scale-associated melanocytes 
appear on the dorsum of the animals. To assay melanocyte gene transcripts, scales were plucked 
from the dorsum of adults and processed for RNA isolation and cDNA synthesis. qPCR analysis 
using primers for SOX10, Mitf, Tyrpb1 and GAPDH was performed. This analysis revealed higher 
levels of the melanocyte transcripts relative to GAPDH. Using this method, we are able to detect a 
transgene from a single scale. Thus, qPCR from premalignant melanocytes provides a sensitive assay 
for measuring SOX10 gene signatures. To test the effect of SOX10 on tumor onset in our zebrafish 
melanoma model, we built a vector for overexpressing SOX10 in melanocytes. We performed 
microinjection of this vector into embryos from zebrafish strains which lack melanocytes. The 
vector rescues melanocytes in these animals, and the rescued melanocytes are fated to become 
melanoma by virtue of a p53 null mutation within the vector. A control GFP vector was injected 
into the same strains and used as a baseline comparison. Melanocyte rescued embryos were raised 
to adulthood and monitored for tumor formation until 80% of animals had tumors, and disease 
free survival curves were tabulated. Median tumor onset was 11 weeks for SOX10 tumors versus 
18 weeks for GFP, with a log-rank test value of p <1 X 10-4. Thus, overexpression of SOX10 accel-
erated melanoma onset in our model. This novel and high-throughput zebrafish melanoma model, 
therefore allows us to functionally test the role of SOX10 in invasive melanoma tumor phenotypes. 
Knowledge from this work offers the potential to definine a transcriptional signature that could serve 
as an early biomarker of invasive disease.    
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Receptor tyrosine kinase inhibitor, Dasatinib, inhibits activity of endogenous EphB2 receptor 
and promotes apoptosis of cutaneous squamous carcinoma cells
M Farshchian,1 L Nissinen,1 R Grénman2 and V Kähäri1 1 Department of Dermatology and 
MediCity Research Laboratory, University of Turku and Turku University Hospital, Turku, 
Finland and 2 Department of Otorhinolaryngology, Head and Neck Surgery, University of 
Turku and Turku University Hospital, Turku, Finland
Receptor tyrosine kinases are known as desirable targets for treatment of different malignancies. 
Dasatinib is a second-generation BCR-ABL inhibitor with high potency regarding BCR-ABL kinase 
inhibition used in the treatment of imatinib-resistant chronic myelogenous leukemia. We have 
studied the effect of dasatinib, and imatinib on activation of endogenous EphB2 and viability and 
signalling pathways of cell lines established from cutaneous SCC (cSCC) (n=7). Treatment of cSCC 
cell lines with dasatinib potently inhibited activation of endogenous EphB2. Treatment of the same 
cells with imatinib had no effect on EphB2 activation. Treatment with dasatinib significantly reduced 
the number of viable cSCC cells in a time-dependent and dose-dependent manner, whereas imatinib 
had no effect. TUNEL assay showed that dasatinib induced apoptosis of cSCC cells. Inhibition of 
Src activation was noted after treatment of cSCC cells with dasatinib. Moreover, dasatinib potently 
inhibited phosphorylation of ERK1/2 and p38 MAPK in cSCC cells. Taken together, these findings 
provide evidence for the potent effect of dasatinib on inhibiting activation of endogenous EphB2 
and viability of cSCC cells, suggesting it as a therapeutic candidate for patients with unresectable 
or metastatic cSCC.    
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Circulating cell-free DNA is increased in sera of Sézary syndrome patients
Z Ying, T Langridge, M Duvic and X Ni Department of Dermatology, The University of Texas 
MD Anderson Cancer Center, Houston, TX
Background: Sézary syndrome (SS), the leukemic variant of cutaneous T-cell lymphoma (CTCL) 
characterized by clonal proliferation of malignant CD4+CD26- central memory T-cells, can arise 
de novo or evolve from Mycosis fungoides. Others have detected elevated levels of circulating 
cell-free DNA (cfDNA) released from metastatic solid tumors. The purpose of this study was to 
determine the level of circulating cfDNA in the sera of SS patients. Methods: Serum samples (n= 86) 
from 20 SS patients with B1/2 blood involvement were collected from at baseline diagnosis/staging 
and during combined immunomodulatory therapy (extracorporeal photopheresis with biological 
response modifiers) at day 2, 1-month, 3-months, 6-months, and 9-12 months. Cell-free DNA 
was extracted using the ChargeSwitch gDNA Serum Kit and quantified using the Qubit assay. The 
amount of genomic DNA per ml serum was calculated. Results: The average level of cfDNA in 
sera of SS patients at baseline was 53.1 ng/ml (7.0-267.5 ng/ml, n=20) and was higher than in the 
healthy donors (30.0 ng/ml, kit control). Fourteen of 20 patients (70%) had ≥ 30.0 ng/ml circulating 
cfDNA. The serum cfDNA levels were correlated with the numbers of circulating CD4+CD26- lym-
phoma cells with the exception of 2 patients (r=0.55, p<0.05). During therapy, the average level 
of circulating cfDNA was 49.7 ng/ml at day 2 (n=16), 49.9 ng/ml at 1-month (n=16), 36.8 ng/ml at 
3-months (n=15), 28.7 ng/ml at 6-months (n=14), and 23.2 ng/ml at 9-12-months (n=4). Responding 
patients had both a decrease in CD4+CD26- lymphoma cells and in cfDNA (51.9 ng/ml at baseline 
and 23.0 ng/ml, at 6-months; p<0.05) by 6-months. In contrast, patients with either stable disease 
or progression had unchanged cfDNA levels (34.1 ng/ml at baseline and 38.4 ng/ml at 6-months; 
p=0.33). Conclusions: Our results suggest that circulating cfDNA are increased at baseline in sera 
of SS patients and decreased in patients responsive to therapy. Studies using cfDNA as biomarkers 
to detect lymphoma-specific clones are under the way.    
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Sphingosine-1-phosphate stimulating CAMP overexpression accelerates development of 
cutaneous SCC
K Park,1 Y Kim,1 A Nielsen-Scott,1 K Shin,2 Y Lee,2 W Holleran,1 S Arron,1 T Mauro,1 
PM Elias1 and Y Uchida1 1 Dermatology, University of California, San Francisco and 2 
Pharmacy, Chungbuk National University, Cheongju, Korea (the Republic of)
Cutaneous squamous cell carcinoma (cSCC) is a common cancer, often initiated by oxidative 
stress, particularly ultraviolet irradiation (UVR). Oxidative stressors upregulate a key innate immune 
element, cathelicidin antimicrobial peptide (CAMP/LL-37) via endoplasmic reticulum (ER) stress-me-
diated, sphingosine-1-phosphate (S1P) signaling. Prior studies showed that CAMP/LL-37 production 
also increases in certain cancers. Yet, why CAMP overproduction occurs and how CAMP could 
increase tumorigenesis remains unknown. We assessed here whether and how CAMP contributes 
to the development of cSCC. CAMP mRNA/protein production was increased significantly higher 
in cSCC cell lines than in normal human keratinocytes (KC). Moreover, exogenous CAMP signifi-
cantly stimulated the growth of cSCC, but not normal KC. We next showed that blockade of the 
CAMP receptor, formyl peptide receptor-like (FPRL) 1 by a specific receptor antagonist (WRW4) 
attenuated cSCC growth. Furthermore, cSCC, but not KC, invaded into a dermal equivalent, and 
exogenous CAMP further stimulated cSCC invasion into an in vitro dermal equivalent, but WRW4 
suppressed cSCC invasion. Finally, elevated CAMP expression and cell growth in SCC were sig-
nificantly suppressed by specific inhibitors of sphingosine kinase 1. Together, these studies suggest 
that S1P signaling stimulates CAMP overproduction rsulting in a FPRL1-dependent enhancement 
of cSCC growth and invasion. Then, excessive production of an innate immune response facilitates 
cSCC tumorigenesis.    
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STAT3-dependent VEGF production from keratinocytes abrogates dendritic cell activation 
and migration by arsenic: a plausible regional mechanism of immunosuppression in arsenical 
cancers
C Hong1, 2, C Lee,3 G Chen,4 K Chang5 and H Yu6 1 Dermatology, Kaohsiung Veterans 
General Hospital, Kaohsiung, Taiwan, 2 Dermatology, National Yang Ming University, Taipei, 
Taiwan, 3 Dermatology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 4 
Dermatology, Kaohsiung Medical University, Kaohsiung, Taiwan, 5 Biochemistry, Kaohsiung 
Medical University, Kaohsiung, Taiwan and 6 National Environmental Toxicology Center, 
NHRI, Zhunan, Taiwan
Arsenic remains an important environmental hazard that causes several human cancers. Arse-
nic-induced Bowen’s disease (As-BD), a skin carcinoma in situ, is the most common arsenical 
cancer. While great strides have been made in our understanding of arsenic carcinogenesis, how 
host immunity contributes to this process remains unknown. Patients with As-BD have an impaired 
contact hypersensitivity response. Although impaired T cell activation has been well-documented 
in arsenical cancers, how dendritic cell (DC), the key cell regulating innate immunity, regulates the 
immune response in arsenical cancers remains unclear. Using myeloid derived DC (MDDC) from 
patients with As-BD and normal controls as well as bone marrow derived DC (BMDC) from mice 
fed with or without arsenic, we measured the migration of DC. As-BD patients showed an impaired 
CCL21-mediated MDDC migration in vitro. Arsenic-fed mice had defective DC migration towards 
popliteal lymph nodes when injected with allogenic BMDCs via foot pad. Using skin from As-BD 
and normal controls, we found an increased expression of STAT3, a transcriptional factor contrib-
uting to impaired DC activation. Arsenic induced STAT3 activation and the production of VEGF 
in keratinocytes. The increase in VEGF was blocked by inhibiting STAT3 with RNA interference or 
pharmaceutically with JSI-124. While VEGF by itself minimally induced the expression of CD86 
and MHC-II in MDDC, arsenic induced-MDDC activation was abolished by VEGF pretreatment. 
We concluded that the STAT3-VEGF axis in keratinocytes inhibits DC migration in the microen-
vironment of As-BD, indicating that cellular interactions play an important role in regulating the 
disease course of arsenical cancers.    
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Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma 
cell proliferation, apoptosis, migration and invasion
C Zhang and W Li Department of Dermatology, Xijing Hospital, Fourth Military Medical 
University, Xi’an, China
Semaphorin 4D (Sema4D) and its receptor, Plexin-B1, are involved in the pathogenesis of squa-
mous cell carcinoma (SCC) by mediating angiogenesis or perineural invasion through the inter-
action between Sema4D expression on SCC cells and Plexin-B1 expression on endothelial cells 
or nerves. Plexin-B1 expression on several types of tumor cells could mediate various, and occa-
sionally opposing effects, including tumor cell survival, proliferation, angiogenesis, invasion and 
metastasis. However, whether Sema4D exerts paracrine or autocrine effects on SCC via Plexin-B1 
remains unclear. We explored the effects of Sema4D/Plexin-B1 interaction on SCC via Plexin-B1 
expressed on the tumor cells. In the present study, we detected the expression of Plexin-B1 and 
Sema4D in cutaneous SCC (cSCC) tissues and in the cSCC cell line A431 and analyzed the effects 
of the Sema4D/Plexin-B1 interaction on cSCC cell proliferation, apoptosis, migration, invasion, 
and related apoptosis proteins were detected, as well as on the signaling pathway downstream of 
Plexin-B1. We observed significantly increased Plexin-B1 and Sema4D expression in keratinocytes 
in cSCC lesions and in A431 cells compared with that in normal skin tissue and in non-malignant 
keratinocytes. Plexin-B1 silencing reduced the growth, proliferation, migration, and invasion, but 
enhanced the apoptosis of A431 cells. P53, Bax, Bcl-2, were detected for demonstrating the mech-
anism involved in apoptosis. Furthermore, Plexin-B1 inhibited the phosphorylation of Akt and 
extracellular signal-regulated protein kinase (Erk). Soluble recombinant Sema4D promoted the 
growth, proliferation, migration and invasion of A431 cells. Akt and Erk phosphorylation is also 
involved in these processes. In conclusion, Plexin-B1 induces cSCC cell proliferation, migration, 
invasion and suppresses cell apoptosis by interacting with Sema4D. Plexin-B1 might serve as a 
useful biomarker and/or as a novel therapeutic target for cSCC.    
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Immunosuppression and ethnicity influence keratinocyte differentiation in kidney transplant 
recipients
JL Johnson1, 2, KJ Green1, 2, JJ Friedewald3 and J Robinson2 1 Pathology, Northwestern 
University, Chicago, IL, 2 Dermatology, Northwestern University, Chicago, IL and 3 
Comprehensive Transplant Center, Northwestern University, Chicago, IL
Kidney transplant recipients (KTRs) have more than 100-fold increased risk of developing squa-
mous cell carcinoma (SCC) than the general public. Immunosuppressive regimens to prevent organ 
rejection increase SCC risk, but the underlying keratinocyte biology is not fully known. SCC arises 
when keratinocytes divide in the presence of ultraviolet light (UVL)-induced DNA damage, become 
mutated, and proliferate rather than differentiating or undergoing apoptosis. We recently showed 
that UVL exposure down-regulates multiple epidermal structural and differentiation proteins, con-
comitant with increased pro-proliferative signaling. While it is known that drugs like azathioprine 
and tacrolimus inhibit DNA repair, their impact on epidermal structure and differentiation remains 
unknown. We derived 17 primary keratinocyte lines from KTRs and recorded the keratinocyte 
donor’s age, sex, ethnicity, duration of immunosuppression, and immunosuppressive drug blood 
levels on the day of the skin biopsy. The 17 lines were grown simultaneously to confluence in 
low calcium-containing medium (0.07 mM), then switched to high calcium-containing medium 
(1.2 mM) for 48 hours to induce differentiation. Expression levels of the differentiation markers 
Desmoglein 1 (Dsg1) and Keratin 10 (K10) and of other epithelial architectural proteins E Cadherin 
(Ecad) and Plakophilin 3 (Pkp3) were evaluated by immunoblot. While Ecad and Pkp3 were similarly 
expressed between the 17 lines, keratinocytes derived from Caucasian (n=7) and Hispanic (n=4) 
KTRs had markedly lower expression of Dsg1 and K10 than those derived from African American 
KTRs (n=6). The duration of immunosuppression (<12 vs. >12 months) also correlated with differ-
ences in differentiation-associated protein levels between cell lines, regardless of keratinocyte donor 
ethnicity. Understanding the impact of immunosuppression on keratinocyte biology may improve 
SCC prevention and treatment in the highly at-risk KTR population.    
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Identification of a pre-programmed metastasis-associated homozygous deletion in Chr2q37.3 
in human melanoma
KL Couts,1 I Nakachi,2 Y Luo,1 H Van,1 A Fujisawa,1 S Robinson,3 W Robinson,3 M Geraci2 
and M Fujita1, 4 1 Dermatology, University of Colorado, AMC, Aurora, CO, 2 Medicine, 
University of Colorado, AMC, Aurora, CO, 3 Medical Oncology, University of Colorado, 
AMC, Aurora, CO and 4 Denver VA Medical Center, Denver, CO
Metastasis is the most common cause of cancer-related death, and there is a growing need to 
understand the biological events governing cancer progression and metastasis. Recent studies have 
suggested that metastatic potential of primary tumors is implanted (pre-programmed) into their 
genetics. To test this, we used SNP arrays to analyze the genomes of 35 melanoma samples; 10 
patient tumors and their passage in a patient-derived xenograft (PDX) model. Our data show primary 
melanoma tumors (F0) develop more genomic changes than metastatic melanoma tumors when 
passaged through generations of the PDX model (F1, F2, F3). Interestingly, in patient-matched 
primary/metastatic tumors, the primary tumor developed nearly identical genomic alterations to 
those in the metastatic tumor (correlation between primary F0 and metastatic F0, R=0.24; primary 
F3 and metastatic F0, R=0.77), implying that metastatic genomic changes are pre-programmed into 
the primary tumor. Most changes that evolved were deletions, including regions in chromosomes 
2, 7, 10 (PTEN region), 15 and 16. A 1.3 Mbp homozygous deletion in chromosome 2 was iden-
tified in a passaged primary tumor (F1-3) and paired metastatic tumor (F0), and the deletion was 
confirmed by copy number PCR. Analysis of SNP array data from a tumor database (cBioPortal.
org, n=336) revealed Chr2q37.3 is deleted in ~15% of human melanomas. Seven genes in this 
region were expressed in melanoma, and we speculated one or more are metastasis suppressors. 
siRNA knockdown and 3-dimensional spheroid invasion assays showed morphological changes 
and enhanced invasion upon knockdown of HDAC4 and UBE2F, indicating they may suppress 
metastasis. In summary, we have identified a novel deletion (Chr2q37.3) that contains potential 
metastasis suppressor genes in melanoma and demonstrate that metastatic melanoma genomic 
changes are pre-programmed into primary melanoma.    
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Sestrin2 positively regulates AKT signaling and survival in human squamous cell carcinoma 
and melanoma cells
B Zhao,1 P Shah,1 A Budanov,2 L Qiang,1 M Ming,1 A Aplin,3 D Sims1 and Y He1 1 University 
of Chicago, Chicago, IL, 2 Virginia Commonwealth University, Richmond, VA and 3 Thomas 
Jefferson University, Philadelphia, PA
Skin cancer is the most common cancer in the United States and is mainly caused by environmental 
UV radiation. Reducing skin cancer incidence is becoming an urgent issue. The stress-inducible 
protein Sestrin2 (Sesn2) plays an important role in maintaining redox and metabolic homeostasis 
and their related pathologies. However, the role of Sesn2 in cancer remains unclear. Here we show 
that UVB radiation induces Sesn2 expression in normal human keratinocytes, mouse skin, normal 
human melanocytes, and melanoma cells. In addition, Sesn2 promotes AKT activation through a 
PTEN-dependent mechanism. Sesn2 deletion or knockdown sensitizes squamous cell carcinoma 
(SCC) cells to 5-fluorouracil-induced apoptosis, and melanoma cells to UVB- and vemurafenib-in-
duced apoptosis. In mice, Sesn2 knockdown suppresses tumor growth from injected human SCC 
and melanoma cells. Lastly, as compared with normal skin, Sesn2 is up-regulated in both human 
skin SCC and melanoma. Our findings demonstrate that Sesn2 promotes AKT activation and sur-
vival in response to UVB stress and chemotherapeutics, and suggest that Sesn2 is oncogenic in 
skin SCC and melanoma.    
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Neurofibroma development is dependent on the presence of peripheral neurons in the tumor 
microenvironment
C Liao,1 S Pradhan,1 Z Chen,1 AJ Patel,1 C Liu,1 RC Booker1 and LQ Le1, 2, 3 1 Department 
of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, 2 Harold C. 
Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX and 3 
UTSW Neurofibromatosis Clinic, University of Texas Southwestern Medical Center, Dallas, TX
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder. Individuals with NF1 
are predisposed to develop multiple types of tumors. Cutaneous neurofibroma is the most prevalent 
among them and affects nearly all NF1 patients. Neurofibroma is a peripheral nerve sheath tumor 
composed of complex tissue structure, including tumorous Schwann cells and non-tumorous neu-
rons, fibroblasts, mast cells, and endothelial cells. Clinically, neurofibromas always develop along 
peripheral nerves and do not metastasize to distant organs, including central nervous system. This 
suggests a unique supportive role of peripheral neurons in neurofibroma formation. The goal of this 
study is to test the hypothesis that neurofibroma development requires the presence of peripheral 
neurons in the tumor microenvironment. We utilized neurofibroma models generated from a type 
of multi-potent precursor cells reside in dermis termed skin-derived precursor cells (SKPs). We have 
previously reported that Nf1-ablated SKPs can be tumor-initiating-cells for neurofibromas due to 
their potential to differentiate into Schwann cells. We analyzed the tumor formations from Nf1-/- SKPs 
allografted into sciatic nerve and subcutaneous tissue. We also established a novel organotypic 
raft culture system for neurofibroma formation with SKPs and peripheral nerve tissues from sciatic 
nerves or dorsal root ganglia. Data from both of our in vitro and in vivo experimental neurofibroma 
models indicated that peripheral nerves are absolutely required for neurofibroma formation. This 
suggests that the interactions between tumorous Schwann cells their surrounding neurons might be 
a viable therapeutic target in neurofibroma therapy.    
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Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prog-
nosis in acral lentiginous melanoma
S Jee1, 2, Y Sheen,2 C Yeh,1 P Chen,1 M Kuo3, 4 and C Chu1, 2 1 Dermatology, College of 
Medicine, National Taiwan University, Taipei, Taiwan, 2 Dermatology, National Taiwan 
University Hospital, Taipei, Taiwan, 3 Graduate Institute of Toxicology, College of Medicine, 
National Taiwan University, Taipei, Taiwan and 4 Institute of Biochemical Sciences, College 
of Life Science, National Taiwan University, Taipei, Taiwan
Insulin-like growth factor-II mRNA-binding protein 3 (IMP-3) is expressed in several malignancies, 
including melanomas. However, the expression of IMP-3 has not been explored in acral lentiginous 
melanoma (ALM). Our purpose was to define the prognostic value of IMP-3 expression in ALMs. 
In this study, IMP-3 expression was analyzed by immunohistochemistry from the 91 patients diag-
nosed with ALM at the National Taiwan University Hospital diagnosed between January 1995 and 
November 2009. Univariate analysis and multivariate analyses for survival, according to clinical 
and histologic tumor behaviors, were performed by means of Cox proportional hazard model. 
Survival curves were plotted by Kaplan-Meier method. IMP-3 was expressed in 71 (78%) of 91 
tumors. IMP-3-positive tumors were associated with poorer overall, disease-free and distant metas-
tasis-free survival than negative tumors (P=0.0002, 0.0109 and 0.0191, respectively). Univariate 
analysis showed that tumor thickness, lymph node metastasis and IMP-3 expression predicted a poor 
outcome. Multivariant survival analysis found that IMP-3 (P=0.0052) proved to be an independent 
prognostic factor for overall survival in ALMs. In summary, IMP-3 is a strong and independent 
prognostic factor for patients with ALM.    
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Genomic drivers of cutaneous squamous cell carcinoma development 
V Chitsazzadeh,3 C Coarfa,4 T Nguyen,5 AK Joseph,2 P Gunaratne,1 X Su,3 DA Wheeler,4 
ER Flores3 and K Tsai3 1 Univ Houston, Houston, TX, 2 Skin&Laser Surgery Associates, 
Pasadena, TX, 3 MD Anderson Cancer Center, Houston, TX, 4 Baylor College of Medicine, 
Houston, TX and 5 Northwest Diagnostics, Houston, TX
Most cutaneous squamous cell carcinomas (cSCC) arise from precancerous actinic keratoses (AK). 
In order to identify novel targets for molecular chemoprevention, we used isogenic human samples 
throughout cSCC development and a UV-driven Hairless mouse model of cSCC to identify genomic 
drivers of cSCC by cross-species analysis. RNA-Seq identified 349 transcripts that were differentially 
expressed across normal skin (NS), AK, and cSCC. mRNA profiles primarily distinguished NS from 
other samples, whereas microRNA profiles could segregate the three groups. Using cross-species 
functional pair analysis (anti-correlated miRNA-mRNA expression) we identified several miRNAs 
(miR-17,-186,-21,-30,-93) and their targets as major promoters of cSCC development. TRANSFAC 
analysis identified ETS2, MAZ, and TCF3 as core transcriptional drivers of progression. Whole exome 
sequencing demonstrated that UVB signature mutations dominate in AKs and cSCCs, with frequent 
mutations in TP53, NOTCH1/2, and CDKN2A, as previously reported. Surprisingly, NS samples 
adjacent to the cSCCs had up to 1200 mutations with no significant overlap with cSCC. Ingenuity 
Variant Analysis identified NOTCH and its coactivators as the functional modules most perturbed 
in cSCCs. Because cSCC shares commonly mutated genes with lung SCC and head & neck SCC 
(HNSCC), we assessed the global similarity of gene expression to other cancers. By this measure, 
cSCC is most similar to HNSCC and its mRNA signature predicts survival in non-HPV-related 
HNSCC. cSCC is also similar to lung SCC as well as basal subtype of breast cancer. Our cross species 
analysis has identified key genomic drivers of cSCC development as potential chemoprevention 
targets and suggests that our model can serve as the basis for validating chemoprevention targets 
in cSCC and molecularly similar cancers such as HNSCC and lung SCC.    
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Basal cell carcinoma originates from multiple stem cell lineages within hair follicle and 
mechanosensory touch dome epithelia
SC Peterson, A Dlugosz and S Wong University of Michigan, Ann Arbor, MI
Basal cell carcinoma (BCC) is caused by deregulation of the Hedgehog (Hh) signaling pathway, most 
commonly through loss of the tumor suppressor Ptch1. Although several studies have previously 
examined the stem cell origin for BCC, the identity of the cells that give rise to these tumors has 
remained controversial. Here, we utilized conditional Ptch1 loss-of-function mice coupled with 
several inducible Cre recombinase drivers to systematically test whether different stem cell popula-
tions in the skin are susceptible to tumorigenesis. We observed that BCC-like lesions efficiently arise 
from hair follicle stem cells within the upper bulge, lower bulge and isthmus. By contrast, tumors 
did not arise from the bulk of the interfollicular epidermis or from transit-amplifying matrix cells. 
Surprisingly, we observed that a subset of epidermal cells residing within mechanosensory touch 
dome (TD) epithelia are extremely susceptible to tumors. Our work further revealed that normal 
TD epithelia activate Hh signaling during homeostasis while displaying a columnar morphology 
reminiscent of BCC palisading. Importantly, we found that sensory nerves are required to activate 
the Hh pathway within the TD niche, and that surgical nerve ablation can inhibit the progression of 
TD-derived BCC-like tumors. Altogether, our findings identify a neural niche for BCC, and indicate 
that these tumors also efficiently originate from multiple stem cell lineages in the hair follicle, but 
not from the interfollicular epidermis.    
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Premature menopause and hematologic neoplasms further characterize xeroderma pigmen-
tosum as a disorder of accelerated aging
JJ DiGiovanna,1 D Tamura,1 M Merideth,2 SG Khan,1 D Angra1 and KH Kraemer1 1 NCI, 
Dermatology Branch, Bethesda, MD and 2 NHGRI, Bethesda, MD
Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder of DNA repair with features 
of premature aging. Acute burning on minimal sun exposure is found in about half of the patients. 
XP patients develop freckle-like pigmented lesions on sun exposed skin before age 2 yr. Continued 
sun exposure of XP children results in poikiloderma, indicating accelerated photo-aging. XP patients 
have a 2,000 to 10,000-fold increase in melanoma and non-melanoma skin cancer, respectively, 
which develops 33 to 60 yr earlier than in the general population. About 25% of the XP patients 
develop severe progressive neurologic degeneration. Serial audiograms documented accelerated 
age-related hearing loss in XP patients with neurodegeneration and in patients with mutations in 
the XPC gene who do not have severe neurodegeneration. Thus hearing loss is another premature 
ageing feature. In analyzing our 40 yr follow-up study of 54 women with XP, we found that 9 of 12 
menopausal women had experienced cessation of menses before 40 years of age. The median age 
of XP women at menopause (31.5 yr) was about 20 yr younger than in the general population (52.9 
yr). Interestingly, the women with premature menopause all had mutations in the XPC gene. These 
results suggest that human ovaries sustain DNA damage and DNA repair plays a role in maintenance 
of normal ovarian function. In addition, 3 male XPC patients developed new hematologic neoplasms: 
one developed myelodysplastic syndrome (MDS) and died at age 20 yr following a bone marrow 
transplant; an African patient died at age 29 yr with a rapidly progressive B cell lymphoma; and one 
died at age 39 yr from myeloid leukemia with MDS. MDS is rare under age 40 years and typically 
occurs after age 60. With better sun protection, early skin cancer detection and treatment we believe 
that more XP patients are surviving into adulthood. They are developing previously unrecognized 
features of premature ageing, including premature menopause and hematologic neoplasms.    
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FRA1 plays an essential role in skin, head and neck cancer cell growth and migration 
X Zhang, J Wu, T Lechler and JY Zhang Duke University, Durham, NC
FRA1 (Fos-related antigen-1) is an AP-1 family gene regulator that generally functions through 
heterodimerization with Jun-group AP-1 members. While other AP-1 factors are known to regulate 
many aspects of epidermal physiology and pathology, the role of FRA1 has remained unclear. Here, 
we demonstrate that FRA1 is highly expressed in skin, head and neck squamous cell carcinoma 
(SCC), and is subject to MEK-dependent phosphorylation in SCC cells. To test the functional rele-
vance of this, we used shRNA-mediated gene silencing to decrease expression of FRA1 in FaDu, 
and CAL27 head neck SCC cells and A431 epidermal SCC cells. We identified two consequences of 
FRA1 loss in these cells – impaired cell proliferation and migration. FRA1 regulation of cell growth 
was distinct from that of c-Jun, a prominent Jun group AP-1 factor. While c-Jun was required for the 
expression of CDK4, a G1/S phase regulator, FRA1 was essential for AKT activation and expression 
of cyclinB1, a G2-M cell cycle regulator whose expression required AKT-activation. In addition, 
FRA1 knockdown impaired F-actin organization and focal adhesion, and markedly slowed cell 
adhesion and scratch-wound induced cell migration. Conversely, expression of the phosphomimetic 
FRA1 mutant (FRA1DD) promoted cell adhesion and migration in a JNK/c-Jun-dependent manner. 
Through gene expression and ChIP-PCR analyses, we identified KIND1, a cytoskeletal regulator 
of β1-integrin signaling, as a common target gene induced by FRA1 and c-Jun. Restoring KIND1 
expression rescued migratory defects induced by FRA1 loss. In agreement with the in vitro data, 
Fadu cells with FRA1-gene silencing displayed markedly reduced rates of subcutaneous tumor 
growth and parenchymal metastasis. Together, these results indicate that FRA1 integrates JNK and 
MEK signaling pathways to promote cell migration in a c-Jun-dependent manner, and acts through 
AKT to promote cancer cell growth. These findings delineate FRA1 signaling cascades as potential 
therapeutic targets for skin, head and neck SCC.    
ABSTRACTS | Carcinogenesis & Cancer Genetics
S20   Journal of Investigative Dermatology (2015), Volume 135
114
Cutaneous neoplasms undergo a dynamic immunoediting process
DR Roop and BJ Kubick Dermatology, University of Colorado AMC, Aurora, CO
During immunoediting, immune cells exert selective pressure against transformed clones, ultimately 
permitting only mutation cascades that either are non-immunogenic or include immune-evasive 
adaptations. This process includes up to three distinct phases: elimination, equilibrium, and escape. 
Studies of fibrosarcoma formation have shown that the equilibrium phase is rate-limiting for many 
cancers and is delineated by antigen-specific T-cell responses. In most cases, loss of antigen presen-
tation mediates the transition to escape. Since immune selective pressure would serve to minimize 
neoplasm heterogeneity and size during the pre-escape phases of immunoediting, we hypothesized 
that equilibrium phase populations may be uniquely vulnerable to chemotherapy and immune 
modulation. To characterize the pre-outgrowth stages of immunoediting and test the efficacy of 
interventions during this interim, we assembled a genetically-engineered mouse model (GEMM) of 
inducible, KRAS-driven carcinogenesis coupled to a fluorescent reporter. We harvest keratinocytes 
from this model for grafting onto both immunocompetent and immune-deficient recipient mice. 
After healing, transformation is induced and the grafts are imaged repeatedly over time via intra-
vital confocal microscopy. In immunocompromised recipients, transformation yields rapid tumor 
formation and growth. In immunocompetent cohorts, we observe a long-term equilibrium phase 
characterized by cyclic growth and regression of clones originating primarily from hair follicles, 
suggesting that this niche may play an early role in carcinogenesis. Contrary to previous studies 
that showed a requirement for strong antigens, our results argue that KRASG12D mutation is suffi-
cient for immunoediting. We find that grafting is essential for observation of this immunoediting, 
possibly because anti-KRASG12D T-cells are otherwise eliminated by thymic negative selection in 
autochthonous GEMMs. These results provide a rationale for the use of prophylactic immunization 
against driver oncogene-derived peptides and also suggest an explanation for the broad failure of 
post-editing cancer vaccination attempts.    
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Smoothened (SMO) resistance is driven by PI3K–Akt signaling in a subset of murine ASZ001 
BCC cells displaying tumor-initiating cell (TIC)-like characteristics 
GC Jin, Y Zhu, A Kim and DR Bickers Dermatology, Columbia University, New York, NY
Sonic hedgehog (Shh)-targeted therapies drive tumor regression in patients with the basal cell 
nevus syndrome (BCNS); however, the lack of apoptosis in regressed tumors, coupled with tumor 
recurrence, suggest that diverse signaling pathways are likely contributing to recurrent tumor growth. 
Accumulating evidence indicates that tumor-initiating cells (TIC) are resistant to current chemother-
apeutic strategies thereby sustaining tumor growth and recurrence. It is known that the resistance of 
BCCs to the topoisomerase inhibitor etoposide involves increased expression of ABCB1 transporters. 
However, the existence of BCC cells resistant to SMO inhibition and the mechanisms that drive this 
resistance are poorly understood. In this study we used murine BCC (ASZ001) cells to determine the 
molecular mechanisms underlying SMO resistance and enhanced cell survival. Using increasing 
concentrations of SMO inhibitors (i.e., vismodegib, cyclopamine, itraconazole) we were able to 
isolate a small fraction (<1%) of ASZ001 cells manifesting sustained resistance to apoptosis. This 
resistant population (BCC-R) displayed a distinct spindle-like morphology and formed colonies 
enriched in cells expressing putative markers of cancer stem cells (e.g., CD34, p63, α6integrin, Bmi-
1). BCC-R cells harbored no detectable SMO mutations and showed substantial reduction in Gli1 
expression (> 90%), indicating that Shh pathway-independent mechanisms underlie cell survival. 
Transcriptome analysis of vismodegib-resistant ASZ001 cells revealed substantial up-regulation of 
the PI3K–Akt–mTOR pathway, in comparison with vismodegib-sensitive cells. Genetic or pharma-
cological Akt inhibition abrogated the vismodegib-resistance of these cells thereby allowing them 
to undergo apoptosis—as assessed by caspase-3 cleavage and TUNEL assay. Our results show that 
Akt1 signaling sustains the survival of SMO-inhibitor-resistant cells, and that targeting Akt1 could 
prevent relapse of BCC growth and enhance tumor eradication in patients with BCNS.    
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Haploinsufficiency of the Ptch1 gene predisposes mice to developing IR-induced BCCs
GY Wang, E Libove, D Tucker and E Epstein Research, Children’s Hospital Oakland Research 
Institute, Oakland, CA
Gorlin syndrome (BCNS) is an autosomal dominant disorder due to mutations in the PATCHED1 
(PTCH1) gene, which encodes a receptor of hedgehog (HH) ligands and represses HH signaling in 
the absence of ligands. Mutated PTCH1 leads to aberrant activation of the HH signaling pathway, 
which is the pivotal driver underlying BCC carcinogenesis in both sporadic and BCNS BCCs. BCNS 
(PTCH1+/-) individuals are very susceptible to developing more BCCs at an earlier age but the 
cellular and molecular basis for this genetic predispositiom to BCCs remains elusive. Therefore we 
assessed how haploinsufficiency of the murine Ptch1 gene contributes to IR-induced BCC carcino-
genesis. Specifically, we treated Ptch1fl/+ K14CreER2 mice with tamoxifen either at age 4 weeks 
(group A) or at 9 weeks (group B) to delete one copy of Ptch1 in K14-expressing keratinocytes. We 
irradiated both groups of mice with IR at mouse age 8 weeks so that at the time of IR, keratinocytes 
in group A mice, like those in BCNS patients, were Ptch1+/-, and mice in group B remained Ptch1+/+ 
but subsequent to recovery from acute damage all mice had Ptch1+/- keratinocytes. We found that 
mice in both groups developed similar amounts of microscopic BCCs at age either 7- or 9-months. 
By age 18-months, the longest time point monitored based on our studies of Ptch1+/- mice, however, 
only mice of group A (3 out of 13 mice) developed visible BCCs; none of the mice of group B (n=30) 
developed visible BCCs (p=0.02). Histologically, these visible BCCs closely resemble human BCCs. 
This finding indicates (i) that haploinsufficiency of the Ptch1 gene limited to keratinocytes (without 
gene deletion in stromal cells) is sufficient to develop visible BCCs and (ii) surprisingly that hap-
loinsufficiency of the Ptch1 gene during acute mutagenic damage dramatically increases eventual 
conversion of microscopic to visible BCCs, probably by affecting acute repair of this damage. To 
gain further insights into this possible mechanism, we are characterizing in vitro cell cycle profiles 
and apoptosis upon IR treatment of keratinocytes from these mice.    
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Slow-cycling cells in cutaneous T-cell lymphoma: A dynamic subpopulation with reduced 
chemosensitivity and increased tumorigenic potential
WT Kittipongdaja, X Wu and SM Schieke Dermatology, Medical College of Wisconsin, 
Milwaukee, WI
Functional heterogeneity among tumor cells has been identified as a major therapeutic obstacle. 
Slow-cycling, tumor-propagating cells represent a subpopulation of treatment-resistant cells that act 
in a stem cell-like manner as a reservoir for tumor maintenance and relapse. Herein, we characterize 
the slow-cycling tumor cell subpopulation in cutaneous T-cell lymphoma (CTCL). Using the human 
CTCL cell line, Hut78, we identified a subpopulation of slow-cycling cells based on increased 
retention of the lipophilic tracer, DiD. A population of relatively label-retaining, DiD(high) cells 
was isolated through cell sorting. This subpopulation showed decreased proliferation compared to 
fast-cycling, DiD(low) cells which lasted for 72 hours, indicating that the slow-cycling phenotype 
was temporary and reversible. Furthermore, DiD(high) cells showed a decreased BrdU uptake 
compared to DiD(low) cells confirming the slow-cycling phenotype. Both subpopulations were 
able to re-establish the original heterogeneous population further indicating their dynamic nature. 
Interestingly, we found a similar, label-retaining population in xenografted tumors. To identify the 
role of the slow-cycling subpopulation for treatment resistance and relapse, we isolated slow- and 
fast-cycling cells that were then treated with doxorubicin. Slow-cycling cells were less sensitive 
towards doxorubicin and showed recovery of live, actively cycling cells 23-30 days after cytotoxic 
doses of doxorubicin. To assess tumor-initiating potential, DiD(low) and (high) cells were injected 
into the skin of NSG mice. Tumor volume was markedly different with slow-cycling cells forming 
significantly larger tumors (850 mm3 vs. 344 mm3; p<0.05). In summary, we identified a slow-cycling 
subpopulation of CTCL cells that showed reduced chemosensitivity and increased tumor-forming 
capacity. Further characterization of this subpopulation may lead to novel therapeutic strategies 
that target the treatment-resistant stem cell-like population in CTCL.    
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Evidence for reciprocal interaction between bone marrow and cutaneous epithelial cells
RJ Morris,1 K Johnson,1 K Boland,1 N Readio,1 H Park,2 D Gordon2 and D Londono2 1 The 
Hormel Institute, University of Minnesota, Austin, MN and 2 Rutgers University, Piscataway, 
NJ
Previous work from our laboratory has documented recruitment of cytokeratin 14 immunoreactive, Y 
chromosome+, GFP+ donor bone marrow derived cells to a subset of female murine tumors (17/45 
of papilloma sections in which an average area occupied by donor cells was 25% (n=14, SD±15) 
in response to classic multi-stage cutaneous carcinogenesis. To probe the mechanism, we have 
determined the interaction of bone marrow adherent cells (BMDCs) with epidermal keratinocytes 
(KCs). First, there appears to be at least a 2-fold increase in cytokeratin- 14 and -15 expressing 
cells in blood and bone marrow during the early stages of skin tumor promotion as measured 
by FACS, immunofluorescence microscopy, and qPCR. Additionally, GFP+ cells from untreated 
K14Cre;mTmG transgenic mice were also found in the bone marrow (5-11/10^6 in a non-random 
distribution). Second, there is reciprocal in vitro migration of KCs and BMDCs (~ three-fold) towards 
each other over control baits such as 3T3 cells, medium without serum, and FBS. Third, both KCs 
and BMDCs migrate in vitro towards CXCL12 (better than controls), and Hmgb1 (high mobility 
group box-1; BMDC twice as well as KCs over controls. Hmgb1 binds to Tlr4 and PDGF1R alpha 
differentially expressed on CD49f+/CD34+ hair follicle stem cells. Fourth, CXCR4 is expressed on 
approximately 27% of CD49f+/CD34+ hair follicle stem cells, suggesting that these cells have the 
capacity to follow gradients of this mobilizing factor. Fifth, grafted GFP+ KCs from K14Cre;mTmG 
mice are found in blood and bone marrow of their wild type recipients at low numbers (1-5/10^6 
at 7-days following grafting) in a nonrandom distribution. In summary, these observations support 
a previously unrecognized systemic contribution to the cutaneous epithelium in a subset of skin 
tumors and suggest BMDCs and KCs may be capable of reciprocal trafficking. Further identification 
of the cells and their attractants is in progress.    
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The role of perlecan in the path to malignancy
KC Suozzi,1 G Zito,2 CJ Ko,1 DX Nyugen3 and V Greco1, 2 1 Department of Dermatology, 
Yale School of Medicine, New Haven, CT, 2 Department of Genetics, Yale Cancer Center, 
New Haven, CT and 3 Department of Pathology, Yale School of Medicine, New Haven, CT
Squamous neoplasms of the skin include on one end of the spectrum, benign, self- regressing ker-
atoacanthomas (KA), and on the other end, invasive malignant squamous cell carcinomas (SCC). 
The factors that mediate regression and malignant transformation in KA versus SCC respectively are 
poorly understood. To identify mutations mediating physiologic tumor regression, we performed an 
exome-sequencing screen in KA and SCC mouse tumors induced with an established protocol that 
utilizes the chemical carcinogen DMBA. We found conserved mutations in the oncogene Hras1 
and in Hspg2, which encodes the heparan sulfate proteoglycan, perlecan. These mutations were 
present in both KA and SCC tumors but for Hspg2, occurred in significantly higher frequency in KA. 
Perlecan has both a structural role as a component of the basement membrane as well as a signaling 
one since it regulates pathways important in proliferation and tumorigenesis. Immunofluorescence 
(IF) staining of KA and SCC tumors revealed that perlecan expression is upregulated along the tumor 
stromal interphase in KA but is compromised in malignant tumors, with irregular, discontinuous 
BM. We hypothesize that the conserved mutation is conferring a gain-of-function phenotype in 
KA, promoting benignity over invasiveness. To further investigate this hypothesis, we examined 
tumor formation in nude mice injected with wt keratinocytes harboring activated Hras mutation 
with or without shRNA mediated perlecan knockdown (KD). Perlecan KD decreased tumor latency 
and led to development of more aggressive SCC tumors when compared to activated HRAS alone. 
Given that perlecan mutations are known to be important in human cancers including melanoma, 
breast and head & neck SCC, our mouse model will help to understand the role of perlecan and 
the transition from a benign to a malignant tumor.    
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Rolling the genetic dice: Neutral and deleterious SMO mutations in drug-resistant basal 
cell carcinoma
S Atwood, K Sarin, J Li, C Yao, NM Urman, AS Chang, JY Tang and A Oro Dermatology, 
Stanford University School of Medicine, Stanford, CA
Basal cell carcinomas (BCCs) carry higher mutation rates than other cutaneous and non-cutaneous 
cancers, yet how these mutations confer tumor growth without deleterious effects remains poorly 
understood. For instance, advanced BCCs acquire resistance to Smoothened (SMO) inhibitors in part 
by extensively mutating SMO, a G-protein coupled receptor that is essential to promote Hedgehog 
signaling, more than any other cancer. We previously identified nine SMO mutations that drive 
the majority of drug resistance in BCC through two distinct mechanisms, induction of constitutive 
activity or disruption of ligand binding. However, the majority of SMO mutations we observe in 
patients have unclear function with 66% of drug-resistant tumors (29/44) bearing recurrent mutations 
and 93% of tumors (41/44) harboring at least one mutation. Here, we identify 28 additional recurrent 
or COSMIC SMO mutations within our resistant BCC population and interrogate their ability to 
promote Hedgehog signaling. We find that each mutation exerts either neutral or negative effects 
on Hedgehog signaling with a subset of mutations abolishing SMO function. This was surprising as 
nearly half of the residues lie in the pivot regions or ligand binding pocket of SMO, which control 
protein activity and binding of SMO inhibitors, respectively. We postulate that tumors have an 
inherent advantage to generate as many genetically different clones as possible to cultivate a com-
petitive environment that forces clonal competition as a way to grow. This theory suggests many 
mutations would have neutral or negative effects on the cell, but a small percentage of clones will 
gain a competitive advantage that is more favorable for the life of the tumor. As sequencing becomes 
a common tool to interrogate the cause of tumor growth and to identify appropriate therapies for 
use in the clinic, our results present a cautionary tale to functionally validate any mutation before 
concluding their ability to exert oncogenic effects.    
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Identification of a role for CSL and PDCD4 interaction in control of fibroblast cell senescence 
and cancer-associated fibroblast activation
S Jo, YS Brooks and G Dotto Cutaneous Biology Research Center, Massachusetts General 
Hospital/Harvard Medical School, Charlestown, MA
Notch/CSL signaling is an important form of cell-cell communication with an established pro-differ-
entiation and tumor suppressing function in the epidermal compartment of the skin. Recently, it has 
been shown that this pathway plays also an important role in the dermal compartment. In particular, 
deletion or silencing of the CSL gene in dermal fibroblasts results in activation of a CAF (Cancer 
Associated Fibroblast) phenotype, with expression of mitogenic and pro-inflammatory cytokines and 
in vivo induction of keratinocyte tumor formation. In order to elucidate the molecular mechanisms 
by which CSL controls dermal fibroblast CAF activation, we have identified Programmed Cell Death 
4 (PDCD4) as a novel CSL-interacting protein. PDCD4 is a multi-functional nuclear/cytoplasmic 
shuttling protein and also known as a tumor suppressor. Here, we show that PDCD4 binds to the 
promoter region of a canonical Notch target gene, Hes1 via CSL protein. As PDCD4 is not a DNA 
binding protein, these findings point to the exciting possibility of CSL-PDCD4 complex formation 
at the transcription regulatory regions of selected genes. Functionally, PDCD4 has a synergistic 
effect with CSL on controlling canonical Notch target gene expression in dermal fibroblasts, but 
not in keratinocytes and HeLa cells, pointing to a likely cell-type specific mode of PDCD4-CSL 
function. Furthermore, human dermal fibroblasts with PDCD4 knockdown by shRNA have a limited 
proliferative potential and undergo premature senescence, as assessed by Senescence-associated 
b-galactosidase activity (SA-b-Gal), which are also shown in CSL-deleted dermal fibroblasts. In 
addition, PDCD4 deficient dermal fibroblasts enhance tumorigenic behavior of keratinocyte-derived 
SCC. Thus, this points to a similarity and possible complementarity of PDCD4 and CSL functions in 
HDFs. These finding could be substantial impact for our understanding of the molecular mechanisms 
by which CSL controls dermal fibroblast senescence and CAF activation.    
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Loss of the autophagy repressor p8 in human dermal fibroblasts causes senescence and 
CAF activation
SG Goruppi1 and G Dotto2 1 Cutaneous Biology Research Center, Massachusetts General 
Hospital, Charlestown, MA and 2 Biochemistry, University of Lausanne, Lausanne, 
Switzerland
The initiation and development of epithelial cancer result from a close interplay with its microen-
vironment, with chronic inflammation, stromal cell senescence and activation of cancer associated 
fibroblasts (CAF) playing primary roles. Stromal cells senescence can result in acquisition of a CAF-
like phenotype, with the production of SASP factors having the potential of enhancing the growth of 
neighboring epithelial cells. In this context, the role of autophagy, a lysosomal degradative process 
key for cellular homeostasis and stress adaptation, is poorly understood. p8 is a HMG-related protein 
strongly induced in response to stress which functions as a context-dependent regulator of gene 
transcription. Accordingly, p8 associates with key transcription factors and/or co-factors like c-Jun, 
p53, FoxO3 and p300. We have previously shown that p8 functions as transcriptional repressor 
of autophagy, in in vitro and in vivo. In present studies, we have found that in primary human 
fibroblasts (HDFs) p8 expression is up-regulated by inducers of CAF phenotype activation like the 
pro-inflammatory cytokine IL1a or TGFß. Our evidence indicates that p8 functions in this context 
as part of a fail-safe mechanism against coordinate control of stromal cell senescence, autophagy 
and CAF activation. p8 silencing by either siRNA or shRNA expression results up-regulation of 
senescence- (p15, p16 and p21) autophagy- (Ulk1, Bnip3 and Ulk3) and CAF- (IL6 and Cox2) effector 
genes. Importantly, expression of these genes is dramatically induced by IL1 a stimulation of HDFs 
with silenced p8. We will present our further evidence linking the impact of p8 on stromal cell 
senescence and CAF activation to dis-regulation of autophagy- effector genes. We propose that p8 
plays an important role in the coordinate control of stromal cell senescence and CAF activation in a 
close interplay with the autophagic process. Elucidation of the underlying regulatory transcriptional 
mechanisms is likely to have substantial translational implications.    
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Tumor-intrinsic PD-1 signaling promotes Merkel cell carcinoma growth
S Kleffel, C Posch, S Fucaloro, MC Joubert, M Thakuria, TS Kupper and T Schatton 
Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, 
Boston, MA
Merkel Cell Carcinoma (MCC) is a rare, but highly aggressive cancer of the skin. Regardless of ther-
apeutic intervention or stage at initial presentation, one in two patients dies from MCC, highlighting 
the need for more effective treatment modalities. Inhibitors of the programmed cell death-1 (PD-
1) immune checkpoint pathway have shown remarkable efficacy against various advanced-stage 
cancers and are currently undergoing clinical testing in MCC patients. PD-1 therapy is believed 
to inhibit tumor progression by activating anticancer immunity via immune cell-specific PD-1 
blockade. Here, we demonstrate PD-1 expression by established MCC lines and clinical tumor 
biopsies, and identify a critical role of MCC cell-intrinsic PD-1 signaling in tumor growth, including 
in the absence of a functional adaptive immune system. In four established MCC cell lines, MKL-
1, MKL-2, MS-1, and WaGa, RT-PCR amplification and sequencing revealed expression of the 
full PD-1 (PDCD1) mRNA coding sequence and immunoblot analysis demonstrated PD-1 protein 
expression. Flow cytometric analysis showed PD-1 surface protein expression by 4/4 MCC lines 
and by CK20+CD45- tumor cells derived from clinical MCC specimens. PD-1 ligation on MCC cells 
induced protumorigenic signaling downstream of the MCC-PD-1 receptor, which was blocked by 
antibodies to MCC-expressed PD-1. Consistently, in vivo administration of a PD-1 blocking antibody 
to highly immunocompromised NSG mice resulted in significant growth inhibition of human MKL-1 
and WaGa xenografts, concomitant with binding of in vivo administered anti-PD-1 antibody to MCC 
target cells. Our results identify MCC-intrinsic PD-1 signaling as a novel tumor growth-accelerating 
mechanism, the blockade of which could enhance the clinical efficacy of PD-1 inhibitors in patients 
afflicted with this often-fatal malignancy.    
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Upregulation of pro-oncogenic Fbxw7 substrates in Merkel cell carcinoma
ME Verhaegen, D Mangelberger, E Nazzal, K Rybski, J Weick, T Vozheiko, D Wilbert and 
A Dlugosz Dermatology, University of Michigan, Ann Arbor, MI
Merkel cell carcinoma (MCC) is a rare and deadly neuroendocrine skin tumor associated with 
clonal integration of a Merkel cell polyomavirus (MCPyV) in about 74% cases worldwide. This 
polyomavirus harbors an early region transforming antigen (TAg) locus encoding a small (s) and 
a tumor-specific truncated large (tL) TAg, predicted to drive tumorigenesis via interaction with 
cellular tumor suppressor and cell cycle regulatory proteins. Overexpression studies in cultured 
cells in vitro have indicated MCPyV sTAg is the pivotal transforming oncogene. We have recently 
shown robust transforming activity of sTAg in vivo in a panel of Keratin 5 promoter-based transgenic 
mouse models. Interestingly, epithelial transformation was strictly dependent on a recently-described 
sTAg domain that binds the tumor suppressor Fbxw7, the substrate-binding component of the SCF 
E3 ubiquitin ligase complex which targets multiple proteins for ubiquitylation and degradation. 
Furthermore, postnatal induction of sTAg using a Cre-inducible transgene also led to epithelial 
transformation accompanied by elevated expression of Fbxw7 target proteins, including cyclin 
E, c-Jun, mTOR and Mcl-1. While MCPyV sTAg-driven transformation is strictly dependent on 
interaction with the Fbxw7 binding domain, the role of the tumor suppressor Fbxw7 has not been 
addressed in human MCCs. Analysis of 12 cell lines in our UM-MCC panel now shows accumulated 
levels of Fbxw7 substrates including c-Jun, Mcl-1, DEK, mTOR, and cyclin E in greater than 80% of 
MCC cell lines, regardless of the MCPyV status. Furthermore, lentiviral-driven TAg inactivation in 
a representative MCPyV-positive MCC line resulted in decreased cellular proliferation, increased 
cell death determined by Trypan Blue assay, a reduction in the mitosis marker phospho-histone H3, 
and loss of Fbxw7 targets. These data suggest deregulation of Fbxw7 and its multiple pro-oncogenic 
target proteins contributes to the pathogenesis of MCC regardless of MCPyV status, and may identify 
critical Fbxw7 substrates as new therapeutic targets.    
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Increased mutant p53 keratinocyte clonal expansion and intraepidermal levels of IL-22 and 
NOS2 in the presence of LC in chronically ultraviolet B (UVB) irradiated skin
C Bürgler, J Lewis and M Girardi Dermatology, Yale School of Medicine, New Haven, CT
UVB light is an inducer of keratinocyte DNA mutations, including within the tumor-suppressor 
p53, and chronic exposure is associated with cutaneous malignancy. We have discovered that 
Langerhans cells (LC) promote p53 mutant keratinocyte clonal expansion independently of αβ or 
γδ T cells. Thus, we sought to quantify within naïve and chronically UVB-irradiated TCRβ-/-δ-/-.
NLC (LC-intact) and TCRβ-/-δ-/-.DTA (LC-deficient) epidermis the expression levels of epithelial 
growth factors implicated in paracrine stimulation of epithelial neoplasia. Epidermal suspensions 
from non-irradiated LC-intact and LC-deficient skin revealed low-level constitutive expression of 
IL-22 within LC-intact epidermis, with levels elevated in the UVB chronically exposed epidermis 
(untreated DTA = 1.0±0.1, untreated NLC = 8.4±2.1, P= 0.0023 NLC vs DTA; DTA+UVB = 1.6±0.1, 
NLC+UVB = 52.5±7.1, P= 0.0013 NLC vs NLC+UVB; P<0.0001 NLC+UVB vs DTA+UVB), but 
with a lack of expression changes in growth factors AREG, IGF-1, and KGF-1. Furthermore, an 
inverse correlation was found with the expression of EGF relative to IL-22. UVB-exposed LC-intact 
epidermis also displayed the highest levels of expression of IL-1β, IL-6, and IL-23a, cytokines 
known to stimulate production of IL-22 by various immune cells. Notably, NOS2, known to foster 
reactive oxygen species within the epidermis after UVB exposure, was also highest in UVB-exposed 
LC-intact epidermis. Short-term purified cultures of LC also showed augmented expression of IL-1β, 
IL-6 and IL-23 that were further increased after in vitro exposure of these cells to UVB, suggesting 
that at least a portion of the observed epidermal expression for these cytokines was due directly 
to LC, as opposed to augmented production by KC in the presence of LC. Taken together, these 
data suggest that LC-intact epidermis demonstrates augmented keratinocyte and/or LC production 
of IL-1β, IL-6, IL23a and NOS2, which in turns supports local production of IL-22 by non-T (e.g. 
NK and/or ILC) cells.    
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Rapamycin alters the metabolic phenotype in human cutaneous T-cell lymphoma
WT Kittipongdaja, X Wu, S Hwang and SM Schieke Dermatology, Medical College of 
Wisconsin, Milwaukee, WI
The mTOR signaling pathway as a master regulator of cell growth and metabolism represents a 
potential target for cancer treatment. Anticancer drugs preferentially target rapidly proliferating 
tumor cells, leaving behind a quiescent, relatively treatment-resistant population of cells. Under-
standing the metabolic phenotype of those tumor cells may allow more effective treatment strategies. 
Herein, we examine the effect of rapamycin on human T-cell lymphoma cell lines and xenograft 
tumors. HH cells were injected into flanks of NSG mice. Treatment with rapamycin (days 12 to 22) 
led to a marked decrease in tumor size as assessed by weight compared to controls (311.6 mg vs. 
27.55 mg, p<0.05). Rapamycin was also shown to decrease proliferation of HH and Hut78 cells 
in vitro. Western blot analysis showed a downregulation of mTORC1/2 activity in tumor tissue 
and cells. Analysis of the metabolic phenotype showed decreased rates of glycolysis and oxidative 
phosphorylation (OXPHOS) in rapamycin-treated HH and Hut78 cells. Interestingly, similar ATP 
levels were maintained indicating that the reduced ATP synthesis met the decreased bioenergetic 
demand of the quiescent cells. The reduction of aerobic glycolysis was associated with decreased 
glucose uptake (0.57 vs. 1.00 relative units, p<0.05) and lactate output (0.59 vs 1.00 relative units, 
p<0.05). Consistent with this, gene expression and protein levels of hexokinase 2 and lactate 
dehydrogenase were downregulated in rapamycin treated lymphoma cells. The same changes were 
demonstrated in xenografted tumors of HH cells from mice treated with rapamycin, indicating a 
similar metabolic phenotype in vivo. In summary, we were able to demonstrate the reduction in 
glycolysis and OXPHOS accompanying the antitumor effect of rapamycin in human CTCL cell 
lines. Whether targeting the metabolic phenotype of the treatment-induced quiescent population 
of tumor cells may serve as a promising treatment strategy, will be the subject of future studies.   
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Complement C5a regulates squamous carcinogenesis
TR Medler,1 AM Forsyth1 and LM Coussens1, 2 1 Cell, Developmental & Cancer Biology, 
Oregon Health & Science University, Portland, OR and 2 Knight Cancer Institute, Oregon 
Health & Science University, Portland, OR
As a co-dominant mediator of inflammation, the complement cascade is critical for lysis of dam-
aged cells, opsonization, and induction of anaphylactoid reactions. Activation of anaphylatoxins 
C3a, C4a, and C5a induces migration of phagocytes, degranulation of mast cells/granulocytes, and 
relaxation of smooth muscle cells in “damaged” tissues. Because these responses are characteristic 
features of solid tumorigenesis, we speculated that complement factors might also regulate chronic 
inflammation accompanying solid tumor development. To address this hypothesis, we evaluated 
a murine model of squamous carcinogenesis (K14-HPV16 mice) where neoplastic progression to 
carcinoma is dependent on B cells, humoral immunity, and activation of FcgR signaling in infiltrat-
ing myeloid cells. Our studies revealed that whereas C3-deficiency failed to alter characteristics 
of cancer development, absence of C5a receptors (C5aR) expressed on myeloid cells attenuated 
neoplastic progression. Moreover, since C3-deficient (-/-) mice cannot generate C5 convertase, we 
reasoned an alternative protease such as those in the coagulation and fibrinolytic pathways (plasmin, 
thrombin, and Factors IXa, Xa, and XIa) directly activated C5a in HPV16/C3-/- mice. Absence of 
urokinase (uPA) in HPV16 mice resulted in absence of C5a and failed premalignant progression 
similar to HPV16/C5aR-/- mice, with benign hyperplasias representing the most frequent terminal 
neoplastic phenotype. To determine if C5a may represent a target for therapeutic intervention, we 
quantitatively evaluated orthotopic growth of HPV16-derived carcinomas in mice treated with a 
C5aR peptide antagonist alone or in combination with chemotherapy. We revealed synergism with 
the combinational therapy and demonstrated that its effects are dependent on CD8 T cells. Together, 
these data reveal significance of plasmin-activated C5a, and demonstrate that components of the 
fibrinolytic and complement pathways are tractable targets for cancer therapy.    
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A counter-intuitive role for caspase 3 in promoting genetic instability and skin carcinogenesis
X Liu Dermatology, Duke University, Durham, NC
Apoptosis and apoptotic caspases are generally considered tumor-suppressive since there are 
involved in the elimination of unwanted or damaged cells. However, the relationship between 
caspases and carcinogenesis has not been thoroughly examined. In this study, we sought to deter-
mine the role of caspase 3 in chemical- and radiation-induced genetic instability and carcinogenesis. 
By use of a non-invasive caspase 3 reporter, we found that that a significant fraction of mammalian 
cells treated with ionizing radiation could survive, despite caspase 3 activation. Moreover, this 
sublethal activation of caspase 3 promoted persistent DNA damage, chromosome aberrations and 
oncogenic transformation. In addition, chemically-induced skin carcinogenesis was significantly 
reduced in mice genetically deficient in caspase 3. We provided strong evidence that activated 
caspase 3 can indeed promote oncogenic transformation in human cells and in mice by inducing 
persistent genetic instability. Since a wide array of environmental and endogenous stressors can 
trigger caspase 3 activation, our findings suggest that rather than acting as a broad inhibitor of 
carcinogenesis, caspase 3 activation may contribute to genome instability and play a pivotal role 
in tumor formation following damage.    
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Downregulation of miR-215 enhances cancer cell migration and invasion in cutaneous squa-
mous cell carcinoma
EB Olasz, BM Michalski, N Duncan, AM Schock, J Lazar, M Neuburg and Z Lazarova 
Dermatology, Medical College of Wisconsin, Milwaukee, WI
MicroRNAs (miRNAs) play a crucial role in tumor progression and metastasis. We, and others, 
recently identified a number of miRNAs that are dysregulated in cutaneous squamous cell carcinoma 
(cSCC). In this study, we investigated the role of the most downregulated miRNA in cSCC tumor 
biology, miR-215. Evaluation of cSCC tumor samples (n=44) by miRNA PCR arrays demonstrated 
that miR-215 was downregulated in 89% of cSCC when compared to normal skin samples (n=15). 
However, lower miR-215 expression was not associated with a higher tumor grade. Gain-of-func-
tion analyses showed that restoration of miR-215 expression decreases cell migration and invasion 
in four cSCC cell lines in vitro. In contrast, further knockdown of miR-215 with specific anti-miR 
resulted in enhancing cellular migration and invasion. Next we examined three potential targets 
of this miRNA which can play a role in the tumor progression. We observed that in vitro miR-215 
overexpression with specific mimic significantly reduces the mRNA levels of all 3 targets especially 
catenin beta interacting protein 1, a negative regulator of the Wnt signaling pathway. Taken together, 
our findings indicate that miR-215 plays a role in cSCC tumor progression and further studies are 
needed to verify its potential role in the epithelial to mesenchymal progression and tumor metastasis.   
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Serum exosomes from metastatic basal cell carcinoma patients confer increased metabolic 
activity in cultured primary human fibroblasts
G Zhu,1 T Antes,2 R Spitale3 and AS Chang1 1 Dermatology, Stanford University School of 
Medicine, Redwood City, CA, 2 Systems Bio, Mountainview, CA and 3 University of Irvine, 
Irvine, CA
Basal cell carcinoma (BCC) is the most common cancer in humans, however, distant metastasis is 
exceedingly rare, and the mechanism by which BCCs distantly metastasizes is not known. Distant 
metastasis is particularly puzzling in light of current literature indicating that BCCs are dependent 
on peri-tumoral stroma for survival. In epithelial cancers, metastatic cancer cells have been reported 
to secrete microRNAs that are critical for cancer-host crosstalk and this could be occurring with 
metastatic BCCs (MBCCs). To investigate this possibility, next-generation sequencing of exosomal 
microRNA from 10 individuals with confirmed MBCCs and 9 individuals with non-metastatic BCCs 
was performed. We identified 127 microRNAs that were significantly different between MBCC and 
non-MBCC sera, including miR-1228 (suppresses p53 in hepatocellular carcinoma) and miR-365 
(altered in cutaneous squamous cell carcinoma). To begin to assess for biologic effects of microRNAs 
from patients with MBCC, the purified exosomes from MBCC and non-MBCC patients were tested on 
cultured human fibroblasts and keratinocytes. In fibroblasts, purified exosomes from MBCC patients 
led to a dose-dependent increase in MTT-reduction activity (p = 0.029) with no effect on Ki-67 
expression. In keratinocytes, purified MBCC exosomes demonstrated dose-dependent decrease in 
MTT-reduction activity (p = 0.021) and Ki-67 expression (p = 0.046). These differential effects suggest 
that MBCC exosomes may alter the metabolic activity of fibroblasts, but not keratinocytes in vitro, 
suggesting a potential role of new tumor-stromal interactions for BCC metastasis. The microRNAs 
identified here serve as a platform for further mechanistic studies.    
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Mitochondrial DNA damage in Asian patients with non-melanoma skin cancer
B Oh, Z Zheng, J Seo and K Chung Department of Dermatology and Cutaneous Biology 
Research Institute, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
Mitochondrial DNA (mtDNA) damage has been reported in a variety of cancers. Here we pres-
ent in Asian skin, the detailed study of the distribution of multiple forms of mtDNA damage in 
nonmelanoma skin cancer (NMSC) compared to histologically normal perilesional dermis and 
epidermis. We examined twelve lesions which included basal cell carcinoma (BCC), squamous cell 
carcinoma (SCC), and perilesional skin. MitoChip analysis was performed on DNA obtained from 
cryostat-embedded specimens. The results showed that a total of 191,130 bases of mtDNA were 
sequenced in the 12 samples, with 190,842 (99.8%) bases assigned by the automated genotyping 
software. All neoplastic lesions examined demonstrated various mtDNA sequence alterations or 
deletions, which were most commonly involved the ND4 and ND5 genes. Notably, 27 mtDNA 
deletion points were observed in SCC lesions compared to normal perilesional skin. In BCC lesions, 
11 mtDNA deletion points were observed. Our findings substantiate the rationale for exploring the 
mitochondrial genome as a biomarker for the early diagnosis of skin cancer, and mtDNA deletion 
quantification in the specific points can also be used as biomarkers of photoaging in the skin.   
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A new functional validation assay to measure resistance drivers in patient BCCs
R Whitson,2 S Atwood,1 K Sarin,2 J Li,2 G Kim,2 M Rezaee,2 MS Ally,2 C Yao,2 AS Chang,2 
JY Tang2 and A Oro2 1 UC Irvine, Irvine, CA and 2 Dermatology, Stanford, Stanford, CA
Basal cell carcinoma (BCC) is the most common cancer and patients with advanced disease lack 
effective treatment options. Hedgehog (HH) signaling is critical for BCC growth and the HH inhibitor, 
Vismodegib, recently received FDA approval for treatment of BCCs. Unfortunately, tumor resistance 
is common, highlighting the need for further understanding of this malignancy. In collaboration 
with the Stanford Hedgehog Consortium, we sequenced human BCCs to examine tumor evolution 
in response to Smo inhibition. We observed HH pathway activation despite treatment with inhib-
itors against this pathway. Novel variants within the HH pathway were enriched in resistant BCCs 
including the HH receptor, Smo. Strikingly, we found that a large proportion of Smo variants restore 
downstream HH activity in the presence of Smo inhibitors. Despite our signaling data, functional 
validation to distinguish resistance drivers from passengers has been a challenge. We developed 
a novel competition assay to test sufficiency of our novel variants. Cells expressing Smo variants 
were labeled with GFP and control cells were labeled with mCherry. Cells were pooled, treated 
with Smo inhibitors, and monitored for growth. Based on initial observations, our assay can detect 
differences in cell number with high sensitivity distinguishing between cell populations with as 
little as 10-15% growth advantage. We utilized our assay to highlight competitive advantage in 
cells expressing SmoW535L and a Gli2 variant lacking Smo responsiveness (Gli2*). We utilized 
this assay to determine that our human-derived novel Smo variants (W281C, L412F, and D473G) 
confer competitive advantage in cells treated with Smo inhibitors. Our clinical-to-bioinformatic 
pipeline has produced novel functional data for previously unknown variants that confer resistance 
signaling and competitive advantage in BCC cells.    
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NOTCH1 inhibition disrupts formation of stratified epithelium in organotypic cell culture 
models of the skin
L Brooks, H Moslehi, LA Ing and S Arron Dermatology, University of California, San 
Francisco, San Francisco, CA
Exomic analysis of more than 100 patient biopsies indicates that deleterious NOTCH1 alleles are 
present in approximately 75% of cutaneous squamous cell carcinomas (cSCCs). This suggests that 
NOTCH1 inhibition is permissive for cSCC development. Moreover, NOTCH1 activity is known to 
suppress hyperproliferation of keratinocytes in vitro. Therefore, NOTCH1 inhibition likely affects 
the probability of cSCC in vivo. We investigated the effects of NOTCH1 inhibition in organotypic 
cell culture (OTC) models of the skin. Normal human keratinocytes derived from neonate foreskins 
readily proliferated and differentiated to form a stratfied epithelium in OTC. A stratified epithelium 
formed when either devitalized dermis or a permeable plastic membrane was used as the OTC 
substrate. In contrast, various immortalized cancer cell lines carrying loss-of-function NOTCH1 
mutations failed to form stratified epithelium in our OTC models. Cell lines that express β-HPV E6 
proteins, which are known to modulate NOTCH1-mediated transcriptional regulation, also failed 
to stratify in OTC. Additionally, pharmacological inhibition of NOTCH1 disrupted formation of 
stratifed epithelium in vitro. Our results indicate that keratinocyte proliferation and differentiation 
are affected by various modes of NOTCH1 inhibition but further investigation is required to fully 
elucidate its precise role in cSCC development.    
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Mutation burden is associated with gender and survival in metastatic melanoma
S Gupta1, 2, M Artomov,1 W Goggins,3 M Daly1 and H Tsao1, 2 1 Massachusetts General 
Hospital, Boston, MA, 2 Harvard Medical School, Boston, MA and 3 The Chinese University 
of Hong Kong, Shatin, Hong Kong
A stage-for-stage female survival advantage in melanoma outcome has been consistently observed 
but remains largely unexplained. Hormonal, immunological, and innate tumor mechanisms have 
been proposed but none established. Recently, female melanoma patients were found to have 
significantly higher frequencies of tumor-associated, antigen-specific T-cells as compared to males, 
and a link between missense mutation burden in melanoma and immunologic response to ipili-
mumab was reported. If gender differences in immunosurveillance leads to differences in tumor 
immunoediting, we hypothesize that female and male melanomas may differ in their burden of 
somatic missense mutations. To explore this hypothesis, we analyzed the mutation spectra in 269 
metastatic melanomas (102 females and 167 males) from The Cancer Genome Atlas (TCGA) and 
found a significantly greater burden of missense mutations among males [male median 299 verse 
female median 213; regression coefficient (RC) 0.38, p-value=0.002]. Analyses were adjusted for 
potential confounders including age at diagnosis, primary tumor site, stage at diagnosis, site of 
sequenced metastatic tumor, and BRAF and NRAS mutation status. In a separate melanoma cohort 
(52 females and 66 males from Cell 2012 Jul 20;150(2):251-63), we found a similar increase in 
exome substitution rates in males [RC 0.356, p-value=0.03]. Since mutation burden has previously 
been linked to immunologic response, we also examined its effect on overall survival. Using “high 
burden” (top tertile) verse “low burden” (bottom tertile) classification of missense mutation burden, 
we found a survival advantage in the high burden group [univariate Hazard Ratio (HR) 0.59, 95% 
CI 0.38 – 0.91; multivariate HR 0.45, 95% CI 0.28 – 0.73]. These results document a complex 
but novel interaction between gender, survival, and mutation burden in melanoma. While these 
analyses are preliminary and ongoing, one model consistent with the observed mutation burden 
difference is increased immune clearance of melanoma in females.    
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Lack of resistant SMO mutations and decreased mutational load of Gorlin-associated basal 
cell cancers explain marked response to smoothened inhibitors
K Sarin,1 M Rezaee,1 P Jaju,1 AS Chang,1 A Oro,1 E Epstein2 and JY Tang1 1 Dermatology, 
Stanford University, Stanford, CA and 2 Dermatology, Children’s Hospital Oakland Research 
Institute, Oakland, CA
Basal cell cancers (BCCs) are driven by dysregulation of the hedgehog pathway, most commonly 
through genetic alterations in PTCH1 and SMO. Smoothened inhibitors (SIs) target the hedgehog 
pathway and are FDA-approved for the treatment of advanced and metastatic BCCs. However, the 
extent and duration of therapy response is heterogeneous among BCCs with reported resistance of 
up to 45%, commonly due to SMO mutations which disrupt drug binding or release autoinhibition. 
Although most BCCs are sporadic, rare individuals with Basal Cell Nevus Syndrome (BCNS) harbor 
germline defects in PTCH1 and often develop hundreds of BCCs throughout their life. BCNS-BCCs 
are exquisitely more responsive to SIs with virtually no evidence of resistance compared with 
sporadic BCCs. To investigate the mechanisms underlying this differential response, we performed 
targeted sequencing for SMO in 50 therapy-naïve BCNS-BCCs and 58 sporadic BCCs. Interestingly 
none of the BCNS-BCCs (0/50) harbored functionally resistant SMO mutations as compared with 
9% of sporadic BCCs (5/58, p= 0.02) demonstrating an inherent lack of intrinsic SI resistance. To 
understand the low rate of acquired resistance in BCNS-BCCs, we performed exome sequencing 
of 21 therapy-naïve BCNS-BCCs and 9 sporadic BCCs. In contrast to sporadic BCCs, BCNS-BCCs 
displayed a markedly decreased mutational load (9.0 mutations/Mb vs. 21.2 mutations/Mb in spo-
radic BCCs, p= 0.05 adjusted for age), reduced UV-induced mutations (5.2 mutations/Mb vs. 15.5 
mutations/Mb in sporadic BCCs, p = 0.06) and less mutations in checkpoint and DNA-repair genes. 
The relative genomic stability of BCNS-BCCs support the reduced acquisition of resistant SMO 
mutations and improved response to SI therapy. Our results explain the decreased intrinsic and 
acquired resistance to SI in BCNS-BCCs and serves as a mechanistic example of how mutational 
load can modulate tumor resistance to targeted therapies.    
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Genome-stabilization by STAT1-induced cancer cell senescence
E Brenner, H Braumüller, T Wieder, D Gransheier, J Bauer and M Röcken Dermatology, 
Eberhard Karls University, Tübingen, Germany
Immunotherapy with tumor- specific T-helper-1 (Th1) cells can reduce tumor burden in patients 
with skin cancer. We could previously show that Th1 cell cytokines IFN-γ and TNF provokes 
senescence, a permanent cell cycle arrest, in a large panel of cancers by activating the tumor 
suppressor protein p16INK4a. To determine the underlying mechanisms, we studied carcinomas in 
mice where the expression of SV40 large T antigen 2 (Tag2) disturbs the cell cycle control through 
inhibition of the tumor suppressors p53 and Rb (β-cancer). In vitro treatment of isolated β-cancer 
cells with IFN-γ and TNF activates p16INK4a, stabilized the hypophosphorylated state of Rb and 
suppressed the transcription factor E2F2. In consequence, treatment with IFN-γ and TNF arrested 
the β-cancer cells in the G1/G0-phase as shown by flow cytometry in vitro. This G1/G0-arrest was 
senescence-associated as, the treated β-cancer cells remained growth arrested after withdrawal of the 
cytokines, strongly expressed nuclear p16INK4a and expressed SA-β-galactosidase. These effects were 
strictly STAT1-dependent as treatment with IFN-γ and TNF failed to induce G1/G0-arrest, p16INK4a 
and SA-β-galactosidase expression in Stat1/ β-cancer cells. More importantly, immunotherapy with 
tumor-specific Th1 cells growth-arrested even the endogenous growth of β-cancers, and induced 
p16INK4a and expression of SA-β-galactosidase even in vivo. In sharp contrast, immunotherapy 
with tumor-specific Th1 cells failed to induce cancer cell senescence in Stat1/ mice also in vivo. 
Searching a genetic explanation for the senescence in Th1 cell-treated β-cancers, we performed 
array comparative genomic hybridization (CGH) of tumors. Tumors from sham-treated mice showed 
severe CGH aberrations, while β-cancers from Th1 cell-treated mice had normal CGHs. In sharp 
contrast, Th1 cell-treatment completely failed to stabilize the genome in Stat1/ mice. These data 
demonstrate that senescence-induction stabilizes the genome, as determined by CGH, and that this 
genome-stabilization strictly depends on STAT1-induced cancer cell senescence.    
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Rapamycin is a chemopreventive and chemotherapeutic agent for RAS-driven epidermal 
squamous cell carcinoma: Evidence from mouse models
C Cataisson,1 H Kitagawa,2 C Hollander,1 PA Dennis2 and SH Yuspa1 1 LCBG, National 
Cancer Institute, Bethesda, MD and 2 Department of Oncology, Kimmel Comprehensive 
Cancer Center at Johns Hopkins Bayview, Baltimore, MD
To examine the effect of rapamycin on RAS-driven epidermal squamous cell tumors, we treated 
mutant K-RasLA2 mice with rapamycin or vehicle by intraperitoneal injection and found that rapa-
mycin prevented the development of squamous skin tumors (0/21 vs 6/24; p=0.04), and also rapidly 
reduced the size of established tumors.To explore this effect we employed a syngeneic xenograft 
model using H-Ras mutant primary murine keratinocytes to determine if rapamycin could influence 
growth of developing or existing squamous skin tumors.As seen in the K-RasLA2 model, rapamycin 
reduced the growth of tumors in a preventive setting and caused shrinkage of established tumors. 
However, upon cessation of treatment there was a rapid rebound and growth of invasive carcinoma. 
Tumor shrinkage was associated with decreased VEGF expression, reduced numbers of myeloid 
derived suppressor cells (MDSCs) in the spleen of tumor-bearing mice and reduced infiltration of 
Foxp3-positive T cells in squamous tumors. Short-term treatment of tumor-bearing mice with rapa-
mycin was associated with reduced circulating G-CSF and a decreased splenic count for MDSCs. 
In vitro, rapamycin blocked the activation of MAPK in keratinocytes transduced with an oncogenic 
ras vector and decreased cell proliferation but did not significantly modify keratinocyte differenti-
ation marker expression. Future analysis will focus on studying the early response to rapamycin in 
stroma versus cancer cells in order to delineate mechanisms responsible for rapid tumor shrinkage 
after mTOR blockade.    
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Whole genome sequencing reveals oncogenic mutations in mycosis fungoides 
LY McGirt,1 P Jia,2 D Baerenwald,3 RJ Duszynski,4 JA Zic,3 J Zwerner,3 Z Zhao2 and 
CM Eischen4 1 Hematology/Oncology, Levine Cancer Institute, Charlotte, NC, 2 Department 
of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, 3 Department 
of Medicine/Division of Dermatology, Vanderbilt University Medical Center, Nashville, TN 
and 4 Department of Pathology, Microbiology and Immunology, Vanderbilt University 
Medical Center, Nashville, TN
Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), and 
advanced disease is associated with significant mortality. Currently, the pathogenesis of MF is 
unknown. Although alterations in gene expression and genetic mutation have been identified, 
none are considered to be consistently pathogenic in MF. Therefore, we performed whole genome 
sequencing of five MF tumor samples and matched normal skin controls to identify mutations. 
Targeted, high-throughput deep-sequencing of genes in 25 MF samples was also done. Each tumor 
had between 17-297 somatic nonsynonymous exonic single nucleotide variants (SNV) and small 
insertions/deletions. Transition mutations (C to T, G to A) were identified in 40-65% of SNVs. Multi-
ple mutations affected similar pathways in the majority of patients, including epigenetic and cell-fate 
regulation, as well as cytokine signaling and regulation. A TP53 polymorphism was also present in 
the majority of MF patients. Identical activating mutations within a cytokine signaling pathway were 
detected in both a tumor and a CTCL cell line. Treatment with a therapeutic targeting the mutation 
led to diminished CTCL cell growth. Although we detected genetic heterogeneity within MF tumors, 
commonly affected pathways were identified and can provide viable targets for treatment in CTCL.   
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Down-regulation of receptor type protein tyrosine phosphatase-kappa promotes squamous 
cell carcinoma
Y Xu, H Yang, Y Xu, J Zhou, K Rybski, JJ Voorhees and GJ Fisher Department of Dermatology, 
University of Michigan, Ann Arbor, MI
Epidermal growth factor receptor (EGFR) plays pivotal roles in the regulation of important cellular 
processes such as proliferation, migration and survival. Aberrant regulation of EGFR function has 
been shown to occur in many tumors of epithelial origin, including squamous cell carcinoma 
(SCC). EGFR function is dependent on auto-phosphorylation of specific tyrosines, which promotes 
assembly of signal transduction complexes that activate down-stream effectors. We have discovered 
that receptor type protein tyrosine phosphatase-kappa (PTPRK) directly dephosphorylates EGFR, 
thereby rendering it inactive and blocking downstream responses. In this study, we examined EGFR 
and PTPRK expression in SCC tumors and SCC cells lines, and PTPRK function in SCC formation 
in a xenograft mouse model. EGFR protein levels were increased in 5 out of 15 (33%) SCC tumor 
samples compared to normal epidermis. Interestingly, PTPRK protein levels were greatly reduced 
in 11 out of 15 (73%) SCC tumor samples. Over-expression of EGFR was detected in 4 out 9 (44%) 
SCC cell lines, whereas reduction of PTPRK was observed in 5 out 9 (55%) SCC cell lines. Therefore, 
down-regulation of PTPRK is more common than EGFR over-expression in SCC tumor samples and 
cell lines. Furthermore, increased expression of PTPRK in SCC cell lines, by transient transfection, 
reduced EGFR activation/phosphorylation by approximately 3-fold and suppressed cell prolifera-
tion by 80% (N=3, p<0.05). In a xenograph mouse model, restoration of PTPRK in SCC cell lines 
completely suppressed the appearance of detectable tumors, or reduced tumor size by 95% (N=6, 
p<0.05). Conversely, shRNA-mediated knockdown of PTPRK promoted SCC tumor formation by 
3.5-fold (N=6, p<0.05) in mice. These data indicate that down-regulation of PTPRK is a heretofore 
unrecognized common driver of SCC. In SCC cells, reduction of PTPRK is sufficient to drive tumor 
formation, independent of increased EGFR expression. PTPRK levels may be a useful biomarker for 
prognosis and choice of anti-EGFR therapies in SCC patients.    
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Cytokine-induced senescence in human cancer cells critically involves Ago2
H Braumüller, J Pahl, T Wieder, E Brenner and M Röcken Dermatology, University Medical 
Center, Tübingen, Germany
Overexpression of an oncogenic version of HRAS (HRASG12V) in normal cells arrests cell division 
permanently, what resulted in the discovery of oncogene-induced senescence (OIS). The original 
description of OIS prompted the idea of senescence as a tumor suppressive mechanism. We recently 
showed for the first time cancer cell –senescence can also be induced by exogenous signals. We 
found that adaptive immunity can induce senescence-defining stable tumor dormancy by activat-
ing the p16INK4a/Rb signaling-pathway through the combined action of the Th1 cytokines interfer-
on-gamma (IFN-γ) and tumor necrosis factor (TNF). Induction of this cytokine-induced senescence is 
dependent on phosphorylation of the CDK inhibitor p16INK4a and consecutive inactivation of the E2F 
family of transcription factors. As argonaute proteins can suppress E2F target genes in doxorubicin-in-
duced senescent human cancer cells, we analyzed the contribution of Ago2 in cytokine-induced 
senescence. After treatment with IFN-γ and TNF the human breast cancer line MCF-7 and the human 
rhabdomyosarcoma line A204 were growth arrested as compared to untreated carcinoma cells. 
To analyze whether these exogenous stimuli induced senescence in human cancer cell lines, we 
performed senescence-associated beta-galactosidase assays and growth arrest assays. Both methods 
confirmed the induction of senescence after cytokine treatment. Subsequently we investigated 
expression and localization of Ago2 after cytokine treatment by immunofluorescence. Independent 
of the senescence Ago2 expression was present in the cytoplasm of all cancer cells. Yet, following 
exposure to the Th1-cytokines, Ago2 translocated from the cytoplasm into the nucleus, exclusively 
in non-proliferating senescent cells, as unraveled by double-staining with the proliferation marker 
Ki67. The translocation started at 24h and continuously increased over the following 72h. The 
strong activation of the E2F-suppressing Ago2 unravels a critical role for cytokine-activated Ago2 
in the senescence-induction of human cancer.    
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Planar cell polarity effector gene INTU mediates the formation of basal cell carcinoma 
through orchestrating ciliogenesis and Hedgehog signaling
N Yang,1 C Liu,1 L Li,3 JE Fitzpatrick,4 EC Jones,2 D Norris,4 A Liu,5 RA Clark,2 DR Roop4, 6, 
KR Shroyer1 and J Chen1, 2 1 Department of Pathology, Stony Brook University, Stony Brook, 
NY, 2 Department of Dermatology, Stony Brook University, Stony Brook, NY, 3 Department 
of Dermatology, Peking Union Medical College Hospital, Beijing, China, 4 Department of 
Dermatology, University of Colorado Denver, Aurora, CO, 5 Department of Biology, Eberly 
College of Science, Pennsylvania State University, University Park, PA and 6 Charles C. Gates 
Center for Regenerative Medicine and Stem Cell Biology, University of Colorado Denver, 
Aurora, CO
Selective inhibition of the hedgehog (Hh) signaling pathway with smoothened (SMO) inhibitors is 
effective for treating locally advanced or metastatic basal cell carcinoma (BCC). The development of 
treatment-resistant tumors in association with SMO inhibitor treatment suggests the need for identify-
ing new therapeutic targets along the Hh signaling pathway. The primary cilium is a cellular organ-
elle that is essential for processing Hh signals. Previously, we demonstrated that Inturned (INTU), a 
planar cell polarity effector gene, is required for ciliogenesis during hair follicle morphogenesis. In 
this study, we show that human BCC cells frequently possess primary cilia. In addition, we found 
that INTU is highly expressed in BCC specimens and that elevated INTU expression often correlates 
with increased primary cilia formation and Hh signaling, suggesting that INTU is required for BCC 
formation. Indeed, disrupting the expression of Intu in a mouse model of BCC, which expresses a 
mutant oncogenic form of Smo, was able to prevent BCC formation. We confirmed that this effect 
was in conjunction with suppressed primary cilia formation and Hh signaling. Thus, data obtained 
from this study suggests that Intu mediates the formation of BCC through orchestrating ciliogenesis 
and Hh signaling, thereby revealing a new avenue to target the Hh signaling pathway in BCC.   
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Bmi-1 differentially regulates p16ink4a and p19arf in p63-overexpressing keratinocytes
RM Ponnamperuma,1 L Ha,1 D Reilly,1 S Jay2 and WC Weinberg1 1 Laboratory of Molecular 
Oncology/OBP, CDER/FDA, Silver Spring, MD and 2 SIAC Frederick, Inc., Bethesda, MD
Overexpression of p63, particularly ΔNp63α, is seen in squamous cell carcinomas of the head and 
neck, lung, cervix and skin. We have previously demonstrated that in primary murine epidermal 
keratinocytes ΔNp63α inhibits induction of p16ink4a and p19arf, blocks oncogene-induced senes-
cence, and enhances malignant conversion in the presence of oncogenic ras. It is well established 
that the INK4a/ARF gene locus is repressed by bmi-1-containing polycomb complexes. To under-
stand the mechanism(s) whereby ΔNp63α regulates INK4a/ARF and its contribution to squamous 
cancer pathogenesis, we evaluated the impact of modulating bmi-1 expression on p16ink4a and 
p19arf levels in v-rasHa keratinocytes in the presence or absence of elevated ΔNp63α. We report 
that in control keratinocytes, endogenous ΔNp63α and bmi-1 levels decline as cultures undergo 
senescence. ΔNp63α levels decrease first, indicating that ΔNp63α may serve as an upstream regu-
lator of bmi-1. In contrast, in ΔNp63α-overexpressing keratinocytes bmi-1 levels remained stable. 
Overexpressing bmi-1 in control keratinocytes reduced p16ink4a expression to levels similar to those 
in ΔNp63α-overexpressing cells, but only minimal inhibition of p19arf was observed. Similarly, 
silencing bmi-1 in ΔNp63α-overexpressing cells by shRNA restored p16ink4a expression, but not 
p19arf expression, to levels similar to those in control lenti-GFP infected cells. These findings are 
consistent with results of ChIP assays. p63 was seen to bind to the promoters of both p16ink4a and 
p19arf in ΔNp63α-overexpressing, but not in lenti-GFP control keratinocytes. Knockdown of bmi-1 
by shRNA prevented the binding of p63 to the p16ink4a promoter, but not to the p19arf promoter. 
These results suggest a specific role for bmi-1 downstream of ΔNp63α in regulating p16ink4a, but 
not p19arf. The relative contributions of p16ink4a and p19arf to tumor phenotype downstream of 
ΔNp63α are under evaluation.    
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A subpopulation of epidermal squamous cell carcinoma stem cells drives formation of rap-
idly-growing and highly-vascularized aggressive tumors
G Adhikary, D Grun, W Xu and R Eckert Biochemistry and Molecular Biology, University of 
Maryland School of Medicine, Baltimore, MD
Epidermal squamous cell carcinoma is among the most common cancers in humans. These tumors 
are comprised of phenotypically diverse cells that display varying potential for proliferation and 
differentiation. An important goal is identifying cancer cells with enhanced ability to form tumors. 
In the present study, we identify and enrich a subpopulation of squamous cell carcinoma tumor 
cells that form aggressive, rapidly growing, highly-vascularized tumors as compared to non-enriched 
tumor cells. These cells form rapidly-growing, large and aggressive tumors in immune-compromised 
mice when as few as one-hundred cells are injected. Cells isolated from these tumors retain an 
enhanced ability to survive and when explanted, grow under conditions that only permit stem cell 
survival. These cells appear to be cancer stem cells, as they are highly enriched for expression 
of epidermal stem cell and embryonic stem cell markers. We also identity key stem cell survival 
factors required for cancer stem cell survival and show that knockdown of these targets attenuates 
tumor formation. These proteins include vascular endothelial growth factor (VEGF) and the Ezh2 
polycomb group protein. Interfering with VEGF or Ezh2 signaling reduces tumor growth and results 
in formation of a reduced number of small, poorly vascularized and non-aggressive tumors. These 
interesting studies identify a subpopulation of epidermal tumor-forming cells that possess stem cell-
like properties and identify survival proteins that are enriched in these cells and represent cancer 
stem cell-specific therapy targets.    
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Keratin-dependent regulation of autoimmune regulator (Aire) and gene expression in skin 
tumor keratinocytes
R Hobbs,1 D DePianto,1 J Jacob,1 M Han,1 B Chung,1 A Batazzi,1 S Ong,2 W Zheng,1 
JM Taube3, 4, D Cˇiháková2, 4, F Wan1, 5, 6 and P Coulombe1, 3, 5 1 Biochemistry and 
Molecular Biology, Johns Hopkins University, Baltimore, MD, 2 Molecular Microbiology 
and Immunology, Johns Hopkins University, Baltimore, MD, 3 Dermatology, Johns Hopkins 
University, Baltimore, MD, 4 Pathology, Johns Hopkins University, Baltimore, MD, 5 
Oncology, Johns Hopkins University, Baltimore, MD and 6 Sidney Kimmel Comprehensive 
Cancer Center, Johns Hopkins University, Baltimore, MD
Expression of the intermediate filament protein keratin 17 (K17) is robustly upregulated in inflam-
matory skin diseases and in many tumors originating in stratified and pseudostratified epithelia. 
We report that Autoimmune regulator (Aire), a transcriptional regulator with a well-known func-
tion in regulating immune tolerance in the thymus, is inducibly expressed in human and mouse 
tumor keratinocytes in a K17-dependent manner and is required for a timely onset of Gli2-induced 
skin tumorigenesis in mice. Induction of Aire mRNA in keratinocytes depends upon a functional 
interaction between K17 and the heterogeneous nuclear ribonucleoprotein hnRNP K. Further, K17 
colocalizes with Aire protein in the nucleus of tumor-prone keratinocytes, and each are bound to 
a specific promoter region featuring a NF-κB consensus sequence in a relevant subset of K17- and 
Aire-dependent pro-inflammatory genes. These findings provide radically new insight into keratin 
intermediate filament and Aire function in skin tumor keratinocytes, along with a molecular basis 
for the K17-dependent amplification of inflammatory and immune responses in diseased epithelia.   
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Identification of the KNSTRN proteome by APEX2 targeting
C Lee,1 A Mah,1 C Nguyen1 and P Khavari1, 2 1 Dermatology, Stanford University, Stanford, 
CA and 2 VA Palo Alto, Palo Alto, CA
Mutations in the kinetochore gene KNSTRN occur in 19% of cutaneous squamous cell carcinomas 
(SCC), the second most common cancer with an annual global incidence in excess of 1 million. 
We identified recurrent KNSTRN mutations concentrated around an ultraviolet signature hotspot 
at codon 24. KinastrinS24F was detected in SCC precursors, disrupted normal chromatid cohesion, 
increased aneuploidy, and enhanced tumorigenesis in vivo. To identify functionally relevant protein 
interactions that underlie the dominant, pro-tumorigenic effects of mutant KNSTRN, we performed 
live-cell proteomic analysis with wild type and cancer-associated mutant KNSTRN in mitotic primary 
keratinocytes using the engineered ascorbate peroxidase APEX2, which is able to target all cellular 
compartments and has a small labeling radius. Wild type and cancer-associated mutant KNSTRN 
tagged with APEX2 localized to the spindle and kinetochore of mitotic primary human keratinocytes, 
consistent with preservation of KNSTRN’s temporospatial relationships. Endogenous proteins bioti-
nylated upon enforced expression of KNSTRN-APEX2 fusions at near-physiologic levels were then 
purified using streptavidin beads and identified by mass spectrometry. Putative protein interactions 
enriched in the presence of wild type KNSTRN as well as candidates enriched in the presence of 
cancer-associated mutant KNSTRN were verified by co-immunoprecipitation and proximity ligation 
analysis. Efforts are underway to characterize these binding proteins as well as study the effects of 
altering their levels on chromatid segregation and tumorigenesis. Our KNSTRN proteome further 
suggests novel protein interactions that shed additional insight on KNSTRN’s role at the kinetochore. 
These data identify new protein-protein interactions essential for maintaining chromatid cohesion 
during faithful cellular replication and suggest new druggable targets for the treatment of SCC.   
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Deficiency of soluble adenylyl cyclase facilitates carcinogenesis
L Ramos,1 A Diaz,1 CA Nardin,2 FM Shaw,2 T Merghoub,3 J Wolchok,3 C Lyssiotis,4 
LC Cantley,4 L Levin,1 J Buck1 and JH Zippin2, 4 1 Pharmacology, Weill Cornell Medical 
College, New York, NY, 2 Dermatology, Weill Cornell Medical College, New York, NY, 
3 Medicine, MSKCC, New York, NY and 4 Meyer Cancer Center, Weill Cornell Medical 
College, New York, NY
The role of cAMP in the development of cancer is controversial, and the sources of cAMP in car-
cinogenesis are poorly defined. We study a novel source of cAMP, the enzyme soluble adenylyl 
cyclase (sAC). sAC is a metabolic sensor and dysregulation of metabolism has been proven to be a 
key aspect of tumorigenesis. This enzyme is downregulated or mislocalized in many cancers (e.g., 
SCC and BCC of the skin, melanoma) as compared to normal control tissue and downregulation of 
sAC is associated with poor clinical outcomes. These data suggested that loss of sAC activity may 
predispose cells to transformation or lead to a more aggressive cancer phenotype. To address this 
question, we developed sAC knockout mice and generated immortalized fibroblasts using the 3T3 
method. Compared to immortalized cells derived from wild type littermates, sAC KO cells exhibited 
a striking elevation in MAPK signaling and a Warburg-like metabolic phenotype; however, these 
sAC KO cells were not transformed. Several oncogenes, which do not transform primary cells on 
their own, complement MAPK activation (e.g., HPV 16 E6) to transform cells. Introduction of these 
oncogenes transformed sAC KO, but not wild type, fibroblasts as demonstrated by loss of contact 
inhibition, growth of colonies in soft agar, and the development of tumors in nude mice. We con-
firmed the transformed phenotype of these sAC KO cells was dependent upon MAPK activation. 
Finally, to determine whether sAC knock mice were more susceptible to the development of cancer 
we exposed mouse skin to the carcinogen DMBA following by bi-weekly application of the mitogen 
TPA for 20 weeks. Loss of sAC expression increased both the prevalence and severity of skin tumor 
formation. Thus, sAC represents a previously unappreciated tumor suppressor protein that regulates 
MAPK signaling and metabolism.    
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Non-migratory Candida albicans-specific CD4 TRM that produce abundant IL-17 are generated 
after cutaneous C. albicans infection
TS Kupper1, 2, 3, C Park,1 RO Emerson,4 X Jiang,1 T Tian,1 JT OMalley,1 R Clark1 and 
RC Fuhlbrigge1 1 Dermatology, Brigham & Women’s Hospital, Boston, MA, 2 Dermatology, 
Harvard Medical School, Boston, MA, 3 Cancer Institute and Oncology, Dana Farber, 
Boston, MA and 4 Adaptive Biotech, Seattle, WA
The biology of skin CD8 TRM after viral infection have been widely studied, but skin CD4 TRM are 
less well characterized. We used a cutaneous Candida albicans infection and examined skin T 
cells during infection (d7) and upon resolution (d30, memory phase). At d30, we found that CD4 T 
cells were abundant in skin, while CD8 T cells were more scarce (CD4:CD8 ratio > 3). Using high 
throughput sequencing (HTS) of the TCR BV gene, expanded clones of skin memory T cells at day 30 
closely overlapped with expanding T cell clones in draining lymph nodes at day 7, consistent with 
the generation of C albicans antigen-specific skin T cells during the immune response. To further 
characterize skin memory T cells after C. albicans infection, we examined cytokine expression by 
T cells extracted from skin. At d30 (memory phase), skin CD4 T cells produced abundant IL-17, 
but less IL-9 and little IFN-γ, in both infected and uninfected skin. Skin CD8 T cells produced little 
IL-17, IFN-γ, and IL-9. We confirmed antigen specificity by showing that skin CD4 T cells produced 
abundant IL-17 when incubated with heat-killed C. albicans. To test whether the IL-17 was produced 
by authentic CD4 TRM cells, we used KAEDE transgenic mice to identify non-migratory CD4 TRM 
cells. KAEDE dye is irreversibly converted from green to red after violet light exposure. At day 30 
after infection (24 hours after violet light exposure to skin), the abundant IL-17 production was 
confined predominantly to the non-migratory photoconverted KAEDE-red cells (CD69+stationary 
TRM), while migratory KAEDE-green T cells that had recently migrated into skin produced little 
IL-17. Taken together, these results suggest that non-migratory C. albicans-specific CD4 TRM cells 
are potent producers of IL-17 and thus may have an important role in protection against subsequent 
C. albicans infection.    
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Dysregulation of soluble adenylyl cycase leads to melanocyte transformation
CA Nardin1, 2, M Park,3 A Bacchiocchi,4 R Halaban4 and JH Zippin2, 5 1 Dermatologie, Centre 
Hospitalier Universitaire de Besançon, Besançon, France, 2 Dermatology, Weill Cornell 
Medical Center, New York, NY, 3 Dermatology, Albert Einstein College of Medicine, New 
York, NY, 4 Dermatology, Yale University, New Haven, CT and 5 Meyer Cancer Center, Weill 
Cornell Medical Center, New York, NY
Most melanomas display an overactivation of the MAPK pathway resulting most commonly from 
activating mutations of BRAF (50%) and NRAS (20%). The MAPK pathway is subject to multiple 
forms of regulation. One example is the cAMP-, protein kinase A-dependent phosphorylation and 
inhibition of C-RAF. cAMP is synthesized by adenylyl cyclases which consist of two classes of 
enzymes, transmembrane adenylyl cyclases and the soluble adenylyl cyclase. sAC is downregulated 
in numerous cancers including melanoma and is mutated in about 10% of melanomas. In addition, 
sAC is differentially localized in benign versus malignant melanocytes suggesting that sAC may play 
a role in melanomagenesis. To investigate the role of sAC in melanocytes we established wildtype 
(WT) and sAC knock-out (KO) immortalized mouse melanocyte cell lines. sAC KO cells exhibit a 
distinct cellular morphology as compared to WT melanocytes. sAC KO melanocytes exhibited an 
activation of both MEK and ERK, an altered cell cycle profile, and displayed a more active growth 
phenotype (p-value < 0.05). Finally, only sAC KO cells were able to form colonies in soft agar 
suggesting that simple loss of sAC expression is sufficient to facilitate transformation of melanocytes 
(p-value < 0.05). These data support our previous work that sAC activity has a key role in the devel-
opment of melanoma. Current work is focused on establishing the mechanism of sAC-dependent 
MAPK regulation, and further confirmation of the role of sAC in melanomagenesis in vivo.    
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Triazole antifungal agents promote UV-DNA damage by increasing oxidative stress
M Gober, H Bashir, A Huang, J Li, C Marshall, V Lee, TW Ridky and J Seykora Dermatology, 
Univ. of Pennsylvania, Philadelphia, PA
Immunosuppression in organ transplant recipients necessitates long-term use of antimicrobial agents 
to prevent potentially fatal infections like aspergillosis. Voriconazole (Vcz), a second generation 
triazole antifungal agent, is the first-line prophylactic therapy for aspergillosis and is used widely 
in immunosuppressed patients. Clinical use of Vcz is associated with an increased incidence of 
cutaneous squamous cell carcinoma (cSCC) leading to significant morbidity. To better understand 
the pro-carcinogenic effect of Vcz, we hypothesized that Vcz may induce UV-induced cSCCs by 
promoting DNA damage. Vcz-treated primary human keratinocytes (PHKs) (25uM) exhibited sig-
nificantly increased DNA damage (P < 0.001) by comet assay compared to mock (DMSO treated) 
UV-irradiated controls. Interestingly, UV-irradiated PHKs treated with fluconazole (Fcz), a first 
generation triazole with no reported clinical association with cSCC, exhibited similarly increased 
DNA damage as the UV-irradiated Vcz treated cells. Levels of phosphorylated 53BP1, a marker 
for DNA damage, and phosphorylated p38MAPK were increased in both Vcz and Fcz treated cells 
compared to mock treated cells supporting the comet assay data. Treatment with either Vcz or 
Fcz lead to significant (P<0.01) increases in 8-oxoG formation (an oxidative stress specific form of 
DNA damage) while no changes in formation or repair of cyclobutane pyrimidine dimers (UVB 
specific DNA damage) were seen. In vitro catalase assay showed that Vcz directly inhibits catalase 
independent of UV or cellular machinery. Collectively the data support the conclusion that Vcz 
and its first generation counterpart Fcz promote UV-induced DNA damage by increasing oxidative 
stress. Although there are no reports of increased cSCC associated with Fcz, the data suggests that 
if Fcz was prescribed as a chronic prophylactic medication as is Vcz, it could promote UV-induced 
DNA damage and increase the risk of cSCC.    
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Combinatorial targeting of Akt1 and SMO synergistically suppresses the growth of UV-in-
duced BCCs in a murine model of basal cell nevus syndrome
A Kim,1 Y Zhu,1 NP Yardley,1 M Athar2 and DR Bickers1 1 Dermatology, Columbia University, 
New York, NY and 2 Dermatology, University of Alabama at Birmingham, Birmingham, AL
Drugs targeting Sonic hedgehog (Shh) signaling in basal cell nevus syndrome (BCNS) patients have 
limitations, including tumor recurrence, acquired drug resistance, and failure to induce apoptosis, 
indicating that Shh targeting alone is insufficient for BCC eradication. Alternate strategies focused 
on identifying additional relevant therapeutic targets are needed. One such target is Akt1, a serine/
threonine protein kinase, known to be directly regulated by the Shh pathway transcription factor 
SOX9 via mTOR; this target also confers resistance to UV-induced apoptosis. Introduction of Akt1 
haplodeficiency into Ptch1+/-/SKH-1 mice prevents the growth of UV-induced BCCs. This led us 
to screen various PI3K and Akt inhibitors currently under investigation for treating other human 
cancers. Akt inhibition concomitantly reduced activating Akt phosphorylations and the proliferation 
of cultured BCC (ASZ001) cells to varying degrees, as assessed by BrdU incorporation. Of these, 
only the alkyl-lysophospholipid analogs perifosine and edelfosine induced apoptosis, as shown 
by increased cleaved caspase-3. Overexpression of constitutively active Akt1 abrogated perifos-
ine-induced apoptosis of these cells. Perifosine, in combination with SMO inhibitors, itraconazole 
or vismodegib, further suppressed BrdU incorporation in ASZ001 cells, verifying the synergistic 
pro-apoptotic and anti-proliferative effects linked to using this combinatorial approach. Orally 
administered perifosine (50 mg/kg, PO BID, twice a day for four weeks) combined with itracon-
azole or vismodegib (100 mg/kg PO BID, twice a day, for four weeks) to chronically UV-irradiated 
Ptch1+/–/SKH-1 mice substantially reduced overall tumor burden and the number of microscopic 
BCCs. Our data confirm the importance of Akt1 signaling in the pathogenesis of BCCs and suggest 
that combinatorial targeting of Akt1 with Shh pathway inhibitors could improve the regression/
eradication of BCCs in patients with BCNS.    
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Response to MAL-based PDT in primary fibroblasts isolated from Xeroderma Pigmentosum 
(XP) and Gorlin Syndrome (GS) patients
A Juarranz,1 A Zamarrón,1 S Lucena,1 S Gonzalez,2 Y Gilaberte,3 M Del Rio4 and F Larcher4 
1 Biology, Autonoma University, Madrid, Spain, 2 Industrial Farmacéutica Cantabria, Madrid, 
Spain, 3 San Jorge Hospital, Huesca, Spain and 4 CIEMAT, Madrid, Spain
Xeroderma Pigmentosum (XP) and Gorlin Syndrome (GS) are both pathologies with high predisposi-
tion to skin cancer. Methyl aminolevulinic acid (MAL) photodynamic therapy (PDT) is an established 
therapeutic modality for actinic keratosis, basal cell carcinoma and in situ squamous cell carci-
noma. This therapy is based on the combination of the photosensitizer (PS), light of an appropiate 
wavelength and oxygen, which triggers the production of reactive oxygen species (ROS), leading to 
tumor cell death. The possibility of using PDT as a preventive treatment for skin cancer constitutes 
a very interesting research area, particularly in immunosuppressed or in XP and GS patients, which 
develop skin cancer with a higher rate than the normal population. We have evaluated the effect 
of MAL-PDT on primary cultures of fibroblasts isolated from GS and XP patients. These fibroblasts 
show characteristics of cancer-associated fibroblasts (CAFs): spindle-shaped mesenchymal cells 
expressing specific markers such as α-smooth muscle actin (α-SMA). We have analysed the response 
to PDT of XP and GS fibroblasts compared to dermal fibroblasts obtained from healthy donors. 
The results indicated that PDT induces a higher death rate in XP and GS fibroblasts than in normal 
fibroblasts. In addition, it is worth noting that the exposition to low doses of UVA or UVB light prior 
to PDT, makes the fibroblasts more sensitive to photodynamic treatment. Given the important role 
of CAFs in the progression of skin cancer, these results are of interest since suggest that XP and GS 
fibroblasts could be a target for PDT.    
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The role of the hemidesmosomal protein BP180 in melanoma progression in vivo
B Hwang1, 2, Z Liu,2 J Brozowski,2 L Lin3, 2, N Li,2 M Su,4 NE Thomas,2 LA Diaz2 and 
Z Liu2 1 Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, 
2 Dermatology, University of North Carolina, Chapel Hill, NC, 3 Oral Biology Program, 
University of North Carolina, Chapel Hill, NC and 4 Pediatrics, University of North Carolina, 
Chapel Hill, NC
BP180 (also termed type XVII collagen) is a transmembrane hemidesmosomal protein and is crucial 
for cell-cell matrix adhesion in dermal-epidermal junction of the skin. Loss of BP180 functions 
caused either by insult of autoantibodies directed against the immunodominant domain of BP180 
termed NC16A or by mutations of the gene encoding BP180 leads to subepidermal blistering. 
Various clinical reports indicated that altered expression of BP180 correlates with melanoma pro-
gression. However, it is unclear whether BP180 is directly involved in melanoma progression. To 
investigate the role of BP180 in melanoma progression, we generated two NC16 domain-specific 
knockout (KO) mouse strains-one with whole body NC16A deletion (termed global ΔNC16A) and 
one with tamoxifen-induced NC16A deletion in the skin at ears (termed skin-ΔNC16A). We then 
tested these NC16A KO mice in B16 mouse melanoma model. As expected, both global ΔNC16A 
and skin-ΔNC16A mice showed dermal-epidermal separation. When global ΔNC16A mice were 
injected at ears with B16 melanoma cells, melanoma progression was significantly increased as 
compared to wild-type (WT) control mice. Lymphatic metastases were seen in all of the tested KO 
mice and none of WT control. To determine whether the increased tumor growth was caused by 
the lack of BP180 globally or locally in the skin, we deleted NC16A domain in the skin at ears by 
topical application of tamoxifen. We found that skin-ΔNC16A mice showed a significantly increased 
melanoma progression and lymphatic metastases similar to global ΔNC16A when injected at ears 
with the same number of B16 melanoma cells. These findings represent the first time demonstration 
suggesting that BP180, as a key hemidesmosomal cell-cell matrix adhesion protein, is directly 
involved in melanoma progression.    
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Comparative evaluation of gene expression induced by RAS oncogenic alleles in mouse and 
human keratinocytes
L Li, C Cataisson, B Flowers, A Michalowski and SH Yuspa CCR/LCBG, National Cancer 
Institute, Bethesda, MD
Oncogenic RAS proteins are drivers for a large number of human cancers. However, genomic 
studies have indicated that specificalleles are mutated or selected for in specific cancers. Acti-
vating mutations in K-ras are predominantly detected in a majority of pancreatic, colorectal, lung 
and billary tract cancers; in contrast, mutations in H-ras or K-ras genes have been detected in a 
relatively small percentage of skin SCC and head and neck cancers. Nevertheless, multiple skin 
SCC developing in melanoma patients shortly after B-RAF inhibitors are delivered have mutations 
in H-ras. In mouse skin carcinogenesis initiated with DMBA,, different promoting agents generate 
tumors with mutations in either predominantly H-ras or a mixture of H-ras and K-ras. Thus tissue 
context and tissue microenvironment may play a pivotal role in selecting mutated cells before cancer 
arises. Using lentiviral vectors, human activating mutants of H-ras, K-ras and N-ras were expressed 
in primary human and mouse keratinocytes. RT-PCR was used to evaluate gene expression in cells 
transduced with the ras mutants. Cxcl1 and Tgf alpha expression were induced by all three ras 
mutants. However, only H-ras and K-ras mutants, but not N-ras mutants, reduced basal k1 and k10 
expression. Total RNA from the ras mutant transduced cells were also subjected to RNA-seq analysis. 
Preliminary analysis indicates that in mouse keratinocytes most of H-ras and K-ras regulated genes 
are overlapping, but the majority of N-ras regulated genes are distinct from H- and K-ras regulated 
genes. Currently, we are evaluating data from both human and mouse keratinocytes to identify the 
common and distinctive pathways that are regulated the three RAS oncogenes.    
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Inhibition of the IGF-1R sensitizes human skin to UVB-induced alterations consistent with 
actinic keratosis
DF Spandau1, 2, SS Tholpady,3 J Weyerbacher,1 DH Southern,1 M Loesch1 and JB Travers1 
1 Dermatology, Indiana University, Indianapolis, IN, 2 Biochemistry & Molecular Biology, 
Indiana University, Indianapolis, IN and 3 Surgery, Indiana University, Indianapolis, IN
Senescent fibroblasts accumulate in the skin of geriatric individuals. As a consequence of senes-
cence, geriatric fibroblasts silence the expression of insulin-like growth factor-1 (IGF-1) which 
leads to an increased susceptibility of geriatric keratinocytes to aberrantly respond to ultraviolet B 
(UVB) irradiation. This inappropriate UVB response in geriatric skin is correlated with an increased 
predisposition to develop aging-associated squamous cell carcinoma. Exogenous IGF-1 provided to 
keratinocytes in geriatric keratinocytes in vivo restores the normal UVB response. In tissue cultures 
of neonatal human keratinocytes, inhibitors of the IGF-1 receptor (IGF-1R) tyrosine kinase can 
mimic the inappropriate UVB response observed in geriatric keratinocytes. Therefore, we sought 
to determine whether topical application of a small molecule inhibitor of the IGF-1R could serve 
as a model for the abnormal UVB response found in geriatric skin. Explants of non-geriatric human 
skin were treated topically with vehicle or 20 uM AG538 (specific IGF-1R inhibitor). Acute UVB 
irradiation of these human skin explants demonstrated that suppression of IGF-1R activity led to 
a significant increase in mitotic basal layer keratinocytes containing UVB-induced DNA damage. 
In order to examine the consequences of chronic UVB irradiation, human skin was engrafted onto 
immunosuppressed mice. Xenografted human skin was topically treated with vehicle or 20 uM 
AG538 twice a week and irradiated with UVB five times per week for 13 weeks. Chronic UVB 
irradiation of skin treated with IGF-1R inhibitor AG538 led to epidermal hyperplasia and clusters 
of basal layer keratinocytes overexpressing p53. These features observed in human actinic keratosis 
were not observed in UVB-irradiated, vehicle-treated xenograft skin. These studies indicate that 
IGF-1R inhibition can augment the pro-carcinogenic effects of UVB in human skin.    
155
Epidermal differentiation protects against Hedgehog pathway-driven tumorigenesis
K Harms,1 M Grachtchouk,1 A Ermilov,1 K Pais,1 A Photenhauer,1 D Wilbert,1 D Metzger,2 
P Chambon2 and A Dlugosz1 1 Dermatology, University of Michigan, Ann Arbor, MI and 2 
IGBMC, Université de Strasbourg, Illkirch, France
Deregulated Hedgehog (Hh) signaling leads to basal cell carcinoma (BCC), which is composed of 
masses of undifferentiated, proliferating epithelial cells resembling basal cells in skin. Although 
BCCs can arise from several progenitor cell populations, the effects of oncogenic Hh signaling 
on differentiating epidermal cells, which represent a large population of potential target cells for 
transformation, are not known. We explored this issue by studying the response of suprabasal 
epidermal cells to the Hh pathway oncogene GLI2A using a Cre-inducible mouse model driven 
by the differentiation-specific K10 promoter. We found that suprabasal expression of GLI2A for 2 
weeks, verified by immunostaining, led to epidermal hyperplasia with up to a 3.8-fold increase in 
epidermal thickness depending on body site. This was accompanied by expansion of the K5-ex-
pressing basal cell compartment and up to a 5.5-fold increase in Ki67-positive basal cells. Nearly 
all of the Ki67+ cells were negative for the GLI2A transgene, suggesting a non-cell-autonomous 
effect of GLI2A-expressing suprabasal cells on neighboring basal cells. Many GLI2A-expressing 
suprabasal cells expressed K17, which is regulated in part by a Gli binding site, suggesting activation 
of a Hh/Gli-driven transcriptional program. In contrast to their induction of K17, GLI2A-expressing 
suprabasal cells almost never co-expressed the basal cell keratin K5, and they retained expression 
of K10. Our data establish that activation of oncogenic Hh signaling in differentiated epidermal 
spinous cells can drive proliferation of neighboring basal cells in a non-cell-autonomous manner. 
However, in contrast to other epithelia where oncogenic stimuli can reprogram differentiated cells 
to form tumors, GLI2A-activated suprabasal cells cannot be coaxed back into a basal cell or BCC-
like phenotype, suggesting that the great majority of epidermal cells that acquire oncogenic Hh 
pathway mutations are eliminated from the skin via terminal differentiation.    
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Epigenomic dysregulation leads to the aberrant expression program of cellular senescence 
BC Capell,1 A Drake,2 G Donahue,2 J Dorsey,2 PP Shah,2 Z Dou,2 J Zhu,2 J Pawlikowski,3 
T Rai,3 C Natale,1 TW Ridky,1 PD Adams3 and SL Berger2 1 Dermatology, University 
of Pennsylvania, Philadelphia, PA, 2 Cell and Developmental Biology, University of 
Pennsylvania, Philadelphia, PA and 3 Beatson Institute, University of Glasgow, Glasgow, 
United Kingdom
Cellular senescence is both a potent tumor suppressive mechanism, as in the case of human nevi, 
as well as a potential contributor to tissue degeneration, as senescent cells accumulate during 
skin aging. Universal to all forms of senescence is the secretion of an array of inflammatory cyto-
kines, chemokines, and proteases known as the senescence-associated secretory phenotype, or 
“SASP”, which are thought to be responsible for the tissue degenerative and carcinogenic potential 
of senescent cells. The role of the epigenome and chromatin organization in the regulation of 
SASP expression has never been explored. Thus, using chromatin-immunoprecipitation followed 
by sequencing (ChIP-seq), RNA-sequencing, and functional assays, we investigated this question 
from a genome-wide perspective. Strikingly, we find that the most highly upregulated SASP genes 
(i.e. IL1A, IL1B, MMP1, IL8) display marked gene-specific increases in both euchromatic H3K4me3, 
as well as in the histone variant and marker of DNA double-strand breaks, γH2A.X. More globally, 
these senescent cells possess large-scale broad domains of co-occurring H3K9me3 and H3K27me3 
marked heterochromatic gains and losses. SASP gene clusters are localized within these domains of 
H3K9me3 and H3K27me3 loss, consistent with a more open permissive chromatin environment and 
their increases in H3K4me3 and γH2A.X. Remarkably, both genetic and pharmacological inhibition 
of the H3K4me3 methyltransferase MLL1 abolishes SASP expression in senescence, thus suggesting 
its requirement for SASP expression and its critical role in the senescence DNA damage response. 
Together, these data highlight a novel role for epigenomic dysregulation in the canonical senescence 
transcriptional program, and offers insight into how chromatin modifiers may be important potential 
therapeutic targets in the senescence response during skin cancer and aging.    
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Srcasm null mice develop UV-induced precancerous lesions
X Yang, S Shankar, K Tsukamoto, M Gober, C Marshall, L Wang, T Dentchev and J Seykora 
Dermatology, Univ. of Penn, Philadelphia, PA
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer and its incidence 
is increasing. A better biological understanding of this UV-induced skin cancer may provide insights 
into new therapies. EGFR and Src tyrosine kinases are primary drivers of cell growth and are nega-
tively regulated by Srcasm. Analysis of human cSCC and related precancerous lesions demonstrates 
activation of Src kinases and decreased Srcasm levels. We hypothesized that deletion of Srcasm 
would promote oncogenic signaling. To test this hypothesis Srcasm null mice and Srcasm lentiviral 
knockdown in human keratinocytes were generated and studied. Protein lysates of skin from Srcasm 
null mice demonstrate activation of EGFR and Src kinases and decreases levels of p53, NICD and 
p21. Activation of the canonical Erk1/2, STAT-3 and PDK-1 oncogenic pathways also was seen in 
Srcasm null lysates. The epidermis of Srcasm null mice exhibits a higher Ki-67 index of 8.7 +/- 2.0 
compared to 1.5 +/- 1.1 in controls (p<0.001). UVB irradiation (500 mJ/cm2 x 15 doses) produced 
precancerous lesions in Srcasm null mice but not in controls; the precancerous lesions show an 
increased Ki-67 index and activation of Src kinases, STAT-3 and PDK-1. Acute UVB (1200 mJ/cm2 
x 1 dose) of Srcasm null mice induced prominent erythema, epidermal necrosis and a prominent 
increase in the TUNEL-positive index (14.0 vs 1.3). Acute UV upregulated the mRNA of oxidative 
stress response genes such as Nrf2 (1.03 in KO vs 0.76 in wt, p<0.05) and NQO1 (1.79 in KO vs 
1.05 in Wt, p<0.01). Srcasm knockdown in human keratinocytes accelerated keratinocyte growth 
130%; by enhancing EGFR/MAPK signaling. In human keratinocytes, Srcasm knockdown promoted 
cell growth after UVB exposure. These data show that loss of Srcasm is associated with increased 
oxidative stress and oncogenic signaling. Loss of Srcasm promotes keratinocyte proliferation post-
UVB exposure and the early stages of UVB-induced cutaneous neoplasia.    
      
      
